**Date: 27 September 2022**

SARS-CoV-2 Variants of Concern Update

This document provides an overview of currently circulating SARS-CoV-2 variants as well as newly identified variants. Characteristics of these variants are monitored and reported including: growth advantage/ transmissibility; disease course/ viral dynamics; clinical features (symptoms and severity); immune evasion, vaccine effectiveness and therapeutics effectiveness; and detection/testing.

All viruses, including SARS-CoV-2, change over time. Most of these changes have little to no impact on the properties of the virus, but some may affect properties such as: how easily it spreads, the associated disease severity, the performance of vaccines, therapeutic medicines, diagnostic tools, or the performance of other public health and social measures.

A selected sub-set of topic areas are comprehensively updated in each issue of this document. The dates stated for section updates relate to when a comprehensive update was performed, although additional data might have been added in the interim. New information included since the previous update is provided in red text.

This issue has been consolidated and condensed. Out-dated information has been removed as necessary.

## Structure of Report

* **Section 1: Key new information**
* **Section 2: Public Health Risk Assessment of circulating variants**
* **Section 3: Evidence base**
* **Section 4: References and appendices**

## Circulating variants across Aotearoa New Zealand:

The Institute of Environmental Science and Research (ESR) reports there are five (sub)variants that each make up 2% or more of the sequenced community samples in Aotearoa New Zealand in the period of 3 to 16 September:

BA.5 ~91% of sequenced community samples

BA.4 ~3% of sequenced community samples

BA.4.6 ~3% of sequenced community samples

BA.2 ~2% of sequenced community samples

For further information regarding the genomic report produced by ESR, please refer to the following. ([link](https://www.esr.cri.nz/our-expertise/covid-19-response/covid19-insights/genomics-insights/))

## Current overall variant risk status:

**There is no strong evidence of large increases in transmissibility or disease severity associated with the most recent variants (those after BA.5). The frequency of BA.4.6 is being closely monitored in New Zealand.**

## Executive Summary


*Section updated: 27 September 2022*

**The pandemic remains in a phase of variants with lower disease severity and moderate immune escape. There are currently no new variants that are considered highly likely to change this situation, but the expectation in the short term is that new Omicron variants with a slight growth advantage will continue to emerge. The development of new Omicron variants, alongside waning immunity, could result in a further wave of infection in the medium (3-6 months) term internationally and in New Zealand.**

SARS-CoV-2 Omicron now has numerous subvariants with large numbers of mutations in differing locations in the genome. Internationally, Omicron (including its subvariants[[1]](#footnote-2)) is the only widely circulating Variant of Concern (VoC, as designated by the WHO). (1, 2) However, whole genome sequencing efforts are falling globally, reducing the ability of surveillance to detect VoCs as they emerge.

BA.5 is the dominant variant internationally. BA.5 is also the dominant variant in New Zealand with a stable prevalence of between 85 – 90% throughout August and early September 2022. Omicron variants identified in New Zealand with a prevalence of more than 2% in mid-September 2022 include BA.2, BA.4, BA.4.6 and BA.5. The variants detected at the New Zealand border are currently similar to those detected in the community, and no variants are overrepresented in hospital surveillance data. New Zealand will continue to monitor variant trends using whole genome sequencing and wastewater testing.

None of the current Omicron variants have demonstrated a clinically relevant increase in disease severity relative to the number of cases. Vaccination, including boosters, remains effective at decreasing the risk of hospitalisation and death from Omicron. It remains difficult to predict the impact of variants here in Aotearoa New Zealand based on overseas trends as our infection history and hybrid-immunity differ from other countries.

There has been a decrease in the effectiveness of monoclonal antibodies over time. There has been no observed change in the efficacy of antivirals. The performance of tests for COVID-19 has not changed.

## Contents

[Structure of Report 1](#_Toc115163831)

[Circulating variants across Aotearoa New Zealand: 2](#_Toc115163832)

[Current overall variant risk status: 2](#_Toc115163833)

[Executive Summary 3](#_Toc115163834)

[Contents 4](#_Toc115163835)

[Section 1 Key updates 6](#_Toc115163836)

[Growth advantage/transmissibility 6](#_Toc115163837)

[Immune evasion, vaccine effectiveness 6](#_Toc115163838)

[Disease course / Clinical features (symptoms and severity) 6](#_Toc115163839)

[Therapeutics effectiveness 6](#_Toc115163840)

[Detection/testing 7](#_Toc115163841)

[Associated documentation 7](#_Toc115163842)

[Key recent documents 7](#_Toc115163843)

[Section 2: Summary of Variants 8](#_Toc115163844)

[Public Health Risk Assessment BA.5 8](#_Toc115163845)

[Public Health Risk assessment for BA.2.75 (Centaurus) 10](#_Toc115163846)

[Public Health Risk assessment for BA.4.6 (Aeterna) 12](#_Toc115163847)

[Other New and Circulating Variants 13](#_Toc115163848)

[Previously Circulating Variants 14](#_Toc115163849)

[New signals 15](#_Toc115163850)

[Section 3: Evidence Base: Omicron 17](#_Toc115163851)

[Growth advantage/ transmissibility 17](#_Toc115163852)

[Immune Evasion / Vaccine effectiveness 19](#_Toc115163853)

[Vaccine Effectiveness in adults – Pfizer 19](#_Toc115163854)

[Omicron: Immunological response to vaccination 21](#_Toc115163855)

[Omicron: Reinfection 23](#_Toc115163856)

[Disease course 24](#_Toc115163857)

[Viral dynamics 24](#_Toc115163858)

[Symptomatology 25](#_Toc115163859)

[Hospitalisation 28](#_Toc115163860)

[ICU admission 29](#_Toc115163861)

[Death 30](#_Toc115163862)

[Therapeutics 31](#_Toc115163863)

[Detection 34](#_Toc115163864)

[PCR 34](#_Toc115163865)

[Rapid Antigen Tests (RATs) 34](#_Toc115163866)

[Section 4: Appendices 36](#_Toc115163867)

[Glossary 36](#_Toc115163868)

[Abbreviations 38](#_Toc115163869)

[Useful Links 39](#_Toc115163870)

[References 40](#_Toc115163871)

# Section 1 Key updates

*Section updated: 27 September 2022*

## Growth advantage/transmissibility

* BA.4.6 has an estimated growth advantage of 6.55% per week (95% CrI[[2]](#footnote-3): 5.53 – 7.57) compared to BA.5 in the UK. (3)
* Over an average 2.3 days of exposure to the index case, the unadjusted risk of Omicron transmission to all close contacts of index cases was 29% (95% CI: 26-31%). Unvaccinated index cases had a 36% (30-42%) risk of transmitting to close contacts, while vaccinated index cases had a 27% (24-30%) risk of transmitting to close contacts. (4)

## Immune evasion, vaccine effectiveness

* People who have had a SARS-CoV-2 infection after vaccination have higher neutralising antibody (nAb) levels compared to those who are vaccinated but have not been infected.
* nAb titres wane at slower rates for people who have had a SARS-CoV-2 infection after vaccination compared to those who are vaccinated but have not been infected.

## Disease course / Clinical features (symptoms and severity)

* A systematic review and meta-analysis assessing the incubation period associated with different SARS-CoV-2 variants published in August 2022 found that the mean incubation period for COVID-19 cases caused by the Omicron variant was 3.42 days.
* Further evidence supports the observation that the Omicron variant tends to be associated with less severe clinical outcomes compared to Delta.

## Therapeutics effectiveness

* Pfizer have [initiated a Phase II trial](https://www.fiercepharma.com/pharma/fda-wants-pfizer-study-covid-rebound-effect-longer-course-paxlovid) testing Paxlovid in immunocompromised patients. The trial will compare 5-, 10-, and 15-day courses of the oral antiviral to investigate the effect of longer dosing in reducing the incidence of rebound infections. Results from this study are expected September 2023.
* Research published in the New England Journal of Medicine reports that three antivirals (Paxlovid, molnupiravir, and remdesivir) retain efficacy against the dominant Omicron sublineages BA.5 and BA.2.75. (5)
* Two pre-prints have assessed the neutralising abilities against Omicron variants and reported that Evusheld has markedly reduced potency against the emerging Omicron sublineage BA.4.6 in *in vitro* studies. (6, 7) Although this is preliminary data, it indicates that Evusheld may not be as effective against this variant which may be significant if this becomes a dominant variant. BA.4.6 has a slight growth advantage compared to other variants but is not currently a dominant variant in New Zealand. (8) However, this variant is showing steady growth in US and UK therefore is being monitored domestically. (8, 9)

## Detection/testing

* Currently there is some emerging evidence that suggests a clinically relevant decrease in the performance of RATs for detection of the Omicron variant. (10, 11) Comparability between studies is limited by difference in study design and objectives. For these reasons it is difficult to compare the results between studies and evidence of reduced sensitivity may not be indicative of device performance.

## Associated documentation

The following documents or ongoing work programmes draw upon the evidence in this document:

* New Variants of Concern Monitoring and preparedness
* Outlook Strategy Group
* New Variant Public Health Risk Assessments

## Key recent documents

In addition to selected recent pre-prints and published studies, key reports used in this update include:

* WHO: Weekly epidemiological update on COVID-19 – 7 September 2022 (2)
* UK Health Security Agency: SARS-CoV-2 Variants of Concern and Variants under Investigation in England, Technical Briefing 45, 9 September 2022 (3)

The WHO Weekly Epidemiology Update on 7 September 2022 (2) reported that:

* The number of sequences submitted to GISAID continues to decline and 99% of submitted sequences (globally) between 5 August and 5September 2022 were the Omicron variant. Among Omicron sequences submitted between 22 August and 28 August, BA.2 lineages represented 3% of sequences, while BA.4 lineages represented 4% and BA.5 lineages represented 87%.
* The WHO reported that ‘BA.2.75, an Omicron descendent lineage under monitoring, still shows a relatively low (0.9% and 1.2% in weeks 33 and 34 respectively) prevalence globally, but a number of countries have observed recent increasing trends.’

# Section 2: Summary of Variants

## Public Health Risk Assessment BA.5

Note: BA.4 and BA.5 have identical spike protein. Many results for these subvariants are reported as combined results on the basis of characterisation using S Gene Target Failure (SGTF).

*Updated: 27 September 2022*

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Overall Risk Assessment\*** | **Confidence level \*\*** | **Assessment and rationale** |
| **Overall growth advantage** | **Increased risk** | **High** | **Evidence of a growth advantage compared to BA.2.**  As at 22 September 2022, BA.5 is the predominant variant in New Zealand.  BA.5 has a reported growth advantage of 11.2% over the previously dominant variant BA.2. The growth in BA.5 observed in the whole genome sequencing of individual testing is consistent with the growth observed in wastewater. As cases of BA.5 were increasing and displacing BA.2 in May and early June, the estimated growth rate of BA.5 for New Zealand was approximately 9% per day or 7 day doubling time. (12) This is consistent with growth advantages observed internationally. |
| **Transmissibility** | **Insufficient data** | **Insufficient data** | No direct data on intrinsic transmissibility and there is no current ability to measure from surveillance data. There is some laboratory evidence that ACE2 binding is increased for BA.5 compared to prior Omicron variants, and BA.5 may have increased infectivity. (13) |
| **Immune evasion** | **Increased risk** | **High** | **There is evidence of increased immune evasion compared to BA.2, based on laboratory data; however, preliminary data suggest no substantial decrease in vaccine effectiveness, but this is subject to revision. Growth advantage is likely mostly due to immune evasion properties, rather than changes to intrinsic transmissibility.**  *Laboratory data*: BA.5 has moderate drop in neutralising antibodies compared to BA.1 and BA.2, and lower protection conferred from vaccination with 3 doses. Less of an impact was associated with ‘hybrid’ protection, e.g., by ‘breakthrough’ infections after vaccination.(14-16)  *Reinfection*: Limited evidence on the rates of reinfection in New Zealand or internationally, including after prior Omicron variant infection. Prior infection with BA.1 or BA.2 provides some protection against BA.5; prior infection with non-Omicron variants is lower.(17-19) |
| **Vaccine Effectiveness** | **Low** | **Low/**  **Moderate** | *Vaccine effectiveness (VE):* Insufficient data for robust assessment of vaccine effectiveness but early data suggest there no indicators of a large change in VE against symptomatic infection from BA.2 to BA.5.(17, 20). One study has observed a decrease in VE against hospitalisation between BA.2 and BA.5, comparing people who had received the booster (3 dose with prior infection) to unvaccinated (with prior infection). No difference was seen for VE mortality. (21) The current epidemiological data, whilst incomplete, is consistent with the neutralisation findings. |
| **Severity** | **Possible increase in risk of hospitalisation** | **Low/ Moderate** | Booster vaccination reported to be associated with a lower risk reduction against BA.5 of hospitalisation (77%) and death (88%) compared to the risk reduction for BA.2 of 92% and 94% respectively. |
| **Therapeutics** | **Low** | **Moderate** | One *in vitro* study shows increased resistance to Evusheld compared to BA.2, (22) whilst another shows it retains activity. (23)  Real-world evidence has indicated that Evusheld, when given to vaccinated people, provides an increased protection against symptomatic and severe COVID-19 compared to booster vaccination alone. (24) |
| **Testing** | **Insufficient Data** | **Insufficient data** |  |
| **Overall Assessment** | | | **There is an increase in overall risk from the previous predominant variant, BA.2. BA.5 is more transmissible compared to BA.2 and is the variant associated with the current wave of cases in New Zealand.** |

\*The ‘Overall risk assessment’ is presented in comparison to the prior or current predominant variant, in this case BA.2. ‘Increased risk’ indicates the assessed variant as worse than the previous predominant variant with regards to that characteristic; ‘no change’ means that the assessed variant poses equivalent risk; and ‘decreased risk’ means that the assessed variant is better than the previous predominant variant.

\*\*‘Confidence level’ indicates the overall quality of data that are available to make the risk assessment: ‘High’ (high quality, robust data); ‘Moderate’ (good data with limitations); ‘Low’ (very little data available). ‘Insufficient data’ indicates that there are no data of reasonable quality on which to base an assessment at this time.

## Public Health Risk assessment for BA.2.75 (Centaurus)

*Updated: 27 September 2022*

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Overall risk assessment\*** | **Confidence level \*\*** | **Assessment and rationale** |
| **Overall growth advantage** | **Increased Risk** | **Moderate** | **Evidence of a growth advantage compared to BA.5.**  **Prevalence in community cases to 2 September in New Zealand is 2% and of border cases is 5%.**  There is evidence that BA.2.75 has a growth advantage against BA.4/5 in some countries (India, Austria, Singapore).  *There are too few samples of BA.2.75 internationally or in New Zealand to determine if the observed growth advantage observed overseas will be replicated in New Zealand. The data requires continued close monitoring.* |
| **Transmissibility** | **Insufficient data** | **Insufficient data** | *There is no direct data on intrinsic transmissibility and there is no current ability to measure this directly from surveillance data* |
| **Immune evasion** | **No change in risk** | **Low** | ***No evidence of increased immune evasion.***  *Mutations suggest that BA.2.75 may have immune evasion potential. However, there is very limited data to evaluate immune evasion against vaccination, prior infection with BA.5, or a combination of the two (hybrid immunity). There are no estimates of vaccine effectiveness against BA.2.75.*  *Laboratory data: Neutralisation studies found that BA.2.75 was similar or slightly less able to neutralise antibodies produced after BA.2 infection and vaccination, compared to BA.4 or BA.5. (25-29) Potentially higher receptor binding compared to other Omicron lineages. There are no data on the ability of BA.2.75 to neutralise antibodies produced after BA.5 infection.* |
| **Severity** | **Insufficient data** | **Insufficient data** | **No evidence of a change in severity compared to BA.5**  *Too few cases have been detected internationally or in New Zealand to evaluate severity. Lab and animal studies suggest mixed results for binding compared to BA.5, (29) but overall pathogenicity similar to BA.5. (30)* |
| **Therapeutics** | **Insufficient data** | **Insufficient data** |  |
| **Testing** | **Insufficient data** | **Insufficient data** |  |
|  | **No change in risk** | | |

\*The ‘Overall risk assessment’ is presented in comparison to the prior or current predominant variant, in this case BA.2. ‘Increased risk’ indicates the assessed variant as worse than the previous predominant variant with regards to that characteristic; ‘no change’ means that the assessed variant poses equivalent risk; and ‘decreased risk’ means that the assessed variant is better than the previous predominant variant.

\*\*‘Confidence level’ indicates the overall quality of data that are available to make the risk assessment: ‘High’ (high quality, robust data); ‘Moderate’ (good data with limitations); ‘Low’ (very little data available). ‘Insufficient data’ indicates that there are no data of reasonable quality on which to base an assessment at this time.

## Public Health Risk assessment for BA.4.6 (Aeterna)

*Updated: 27 September 2022*

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Overall risk assessment\*** | **Confidence level \*\*** | **Assessment and rationale** |
| **Overall growth advantage** | **Increased risk** | **Low** | **Evidence of a growth advantage compared to BA.4/5.**  BA4.6 prevalence has slowly increased in NZ, now accounting for approximately 4% of genomes tested in the two weeks to 2 September. |
| **Transmissibility** | **Insufficient data** | **Insufficient data** |  |
| **Immune evasion** | **No change in risk** | **Low** | Early data shows that BA.4.6 has greater immune escape from vaccine serum than BA.5, showing on average 2.4 to 2.6-fold decrease in antibody neutralisation. (6) |
| **Severity** | **Insufficient data** | **Insufficient data** |  |
| **Therapeutics** | **Increased risk** | **Low** | Some indication that Evusheld is less effective for this variant. (6) |
| **Testing** | **Insufficient Data** | **Insufficient Data** |  |
|  | **No change in risk** | | |

## Other New and Circulating Variants

*Updated: 27 September 2022*

| **Pango lineage** | **Other label** | **Earliest documented samples** | **International Detection** | **Detection in NZ** |
| --- | --- | --- | --- | --- |
| **BA.4.6** | Not yet designated | USA, May 2022. (31) | Detected in GISAID in the past 12 weeks (as at 13 September) across 19 different countries including the UK. (9) | Detected in 2 weeks to 8 September |
| **BA.2.10.X** | Not yet designated | India, 02 July 2022. (BA.2.10.1) (32) | Detected in GISAID in the past 12 weeks (as at 9 August), predominantly in India. (32) | Not detected in 2 weeks to 8 September |
| **BA.5.2.1** | Not yet designated | China, 08 July 2022 (33) | Detected in GISAID in the past 12 weeks (as at 13 September) across 19 different countries including the UK. (9) | Not detected in 2 weeks to 8 September |
| **BA.2.75** | Omicron sub-lineage BA.2.75 | India, 02 June 2022 | Detected in GISAID in the past 12 weeks across 15 different countries including the UK (as at 13 September). (9) | Variant of Interest as of 07 July 2022 (34) |
| **BA.4** | Omicron sub-lineage BA.4 | South Africa, January 2022. (35) | Detected in the UK in the past 12 weeks as at 28 August. (3) | Detected in 2 weeks to 8 September |
| **BA.5** | Omicron sub-lineage BA.5 | South Africa, February 2022. (35) | Dominant globally as at 13 September. (9) | Detected in 2 weeks to 8 September |
| **BA.2.12.1** |  |  | Not detected in the UK in the past week as at 28 August. (3) | Not detected in 2 weeks to 8 September |
| **BA.2** | Omicron |  | Detected in the UK in the past 12 weeks as at 28 August. (3) | Detected in 2 weeks to 8 September |
| **BA.3** | - | South Africa (36) | Not detected in the UK in the past week as at 28 August. (3) | Not detected in 2 weeks to 8 September |

## Previously Circulating Variants

*Updated: 27 September 2022*

| **Pango lineage** | **Other label** | **International Detection** | **Latest Detection**  **NZ Community** | **Latest Detection NZ Border** |
| --- | --- | --- | --- | --- |
| **BA.1** | Omicron | Not detected in the UK in the past week as at 28 August. (3) |  |  |
| **Delta and Omicron recombinant lineages (UK)** | - | Detected in the UK in the past 12 weeks as at 22 July.(37) |  |  |
| **AY.119.2/BA.1.1 Recombinant** |  | Not detected in the UK in the past 12 weeks as at 22 July.(37) |  |  |
| **XD Recombinant (Delta x BA.1)** |  | Not detected in the UK in the past 12 weeks as at 22 July.(37) |  |  |
| **XE Recombinant (BA.1 x BA.2)** |  | Detected in the UK in the past 12 weeks as at 22 July.(37) |  |  |
| **AY.119.2/BA.1.1 Recombinant** |  | Not detected in the UK in the past 12 weeks as at 22 July.(37) |  |  |
| **BA.1/BA.2 Recombinant (with unique mutation C3583T)** |  | Detected in the UK in the past 12 weeks as at 22 July.(37) |  |  |
| **XF Recombinant** |  | Not detected in the UK in the past 12 weeks as at 22 July.(37) |  |  |
| **B.1.617.2 and sub-lineages** | Delta | Detected in the UK in the past 12 weeks as at 22 July.(37) | March 2022 | March 2022 |
| **B.1.1.7** | Alpha | Detected in GISAID, but not in the UK, in the past 12 weeks as at 22 July.(37) |  |  |

## New signals

*Section updated: 27 September 2022*

The risk of clinically significant emerging variants is considered to be high, according to the WHO. (38) The WHO has expressed concern in early April, some countries have significantly reduced SARS-CoV-2 testing. They caution that unless robust surveillance systems are retained, countries may lose the ability to accurately interpret epidemiological trends, implement the appropriate measures necessary to reduce transmission and monitor and assess the evolution of the virus. (39) Details of BA.4.6, BA.5 and BA.2.75 can be found above in the risk assessment.

#### BQ.1.1

* An Omicron subvariant that is most closely related to the BA.5 subvariant. First flagged on 26 August 2022 with sequences from the USA, UK and Japan. (40)
* Spike protein mutational profile is the same as BA.5 with the following mutations: R346T, K444T and N460K.
* One BQ.1.1 *in vitro* study showed increased resistance to Evusheld and bebtelovimab. (41)

#### BA.2.3.20

* A BA.2 and Delta recombinant that has a growth advantages over BA.5. (41) Variant has been detected in three countries distant from one another has rare 2-nucleotide mutation S:A484R. First detected in the United States and has since been detected in Singapore. (42)

#### BJ.1

* Detected on the 29July 2022, is a BA.2 sub-lineage with 14 additional mutations in the spike protein, this variant has been mostly detected in India (70% of all BJ.1 cases) and has also been detected in Singapore, South Korea, Austria and the United States of America. (32, 43)

#### BA.2.10.X

* BA.2.10.X (also referred to as BA.2.10.1, BA.2.10.4 or BA.2.10+) is an Omicron subvariant, that has been identified due to its large collection of mutations. There is no observed evidence for phenotypic changes (transmission, severity, immune evasion), and there are very few reported cases of this variant to date.(32)

#### BA.2.75.2

* A pre-print study has found BA.2.75.2 to be resistant to neutralisation by Evusheld (tixagevimab and cilgavimab), but has remained sensitive to bebtelovimab. (44)
* Serum from blood doners in Sweden was on average five-fold less effective at neutralising BA.2.75.2 compared to BA.5. (44)
* BA.2.75.2 is carrying additional mutations, R346T, F486S, and D1199N that due to its growth advantage are suggestive of more extensive escape from neutralising antibodies than previous Omicron variants. (44)

#### BA.5.2.1

* A new subvariant of the Omicron BA.5 lineage detected in China on the 8 July 2022.(33) The first confirmed case of BA.5.2.1 was detected in Shanghai, with more cases since identified across multiple provinces in China.(33) There is limited scientific evidence around transmission potential, disease severity and other properties of this variant.

# Section 3: Evidence Base: Omicron

## Growth advantage/ transmissibility

*Section updated: 27 September 2022*

##### Omicron is more transmissible and has a higher secondary attack rate than Delta

* A study estimated that Omicron (B1.1.529) had a growth advantage that corresponds to a 5.4-fold (95% CI = 3.1–10.1) weekly increase in cases compared with Delta. (45)
* Data from Denmark (to 18 Dec 2021), the effective reproduction number of Omicron is 3.19 (95%CI 2.82–3.61) times greater than Delta under the same epidemiological conditions. (46)
* Data from Texas, USA, indicated a case-doubling time for Omicron of 1.8 days, three times faster than for Delta in this area. (47)
* Data from the UK estimated a shorter generation time (interval between infection events) for Omicron with a mean of 1.5-3.2 days (standard deviation [SD] 1.3-4.6 days), compared to a mean of 2.5-4 days (SD 1.9-3 days) for Delta. (48)
* UKHSA analysis of contact-tracing data shows the mean serial interval for BA.1 is 3.72 days (95% CI: 3.62 - 3.80). (49)
* BA.4 and BA.5 are estimated to have had a daily growth advantage of 0.08 (95% CI: 0.08–0.09) and 0.10 (95% CI: 0.09–0.11), respectively, relative to BA.2 in South Africa in May 2022. (50)
* BA.4.6 has an estimated growth advantage of 6.55% (95% CrI[[3]](#footnote-4): 5.53 – 7.57) compared to BA.5 in the UK. (3)

##### Household transmission

* Secondary Attack Rate (SAR) of 29% for BA.1 compared with an SAR of 39% for BA.2 across households infected with Omicron. (51)
* SAR for Omicron ranges from 7.6% to 50% depending on country and setting. (52-54)
* Over an average 2.3 days of exposure to the index case, the unadjusted risk of Omicron transmission to all close contacts of index cases was 29% (95% CI: 26-31%). Unvaccinated index cases had a 36% (30-42%) risk of transmitting to close contacts, while vaccinated index cases had a 27% (24-30%) risk of transmitting to close contacts. (4)

##### Other data

* The Omicron variant has a survival time in the environment of 21.1 hours (95% CI: 15.8–27.6) compared to 16.8 hours (95% CI: 13.1–21.1) for Delta. (55) The high environmental stability of Omicron could increase the risk of contact transmission and contribute to its spread. However, convincing evidence of fomite transmission has not been demonstrated for any variant to date.
* A study found that initial testing of HCWs if they had a household positive case in majority of instances, was sufficient to prevent nosocomial transmission to patients. (56)
* A human challenge study using **wild-type virus** found that a dosage of 10 TCID50 (very low dose) was sufficient to result in an infection. Also, they found that viral shedding occurs in both the nose and throat at high levels irrespective of symptom severity. (57)

## Immune Evasion / Vaccine effectiveness

### Vaccine Effectiveness in adults – Pfizer

*Section updated: 27 September 2022*

Please note: Current COVID-19 vaccines authorised in New Zealand are based on the ancestral strain of the SARS-CoV-2 virus (wild type or Wuhan-strain).

Vaccine effectiveness against Omicron related infection, hospitalisation and death is lower than prior variants and may wane more rapidly than for previous COVID-19 variants. (58)

##### VE against infection

Primary Course (2 doses)

VE against infection with Omicron is estimated at 40- 55% within 14-30 days after 2 doses of Pfizer. (58, 59) However, the VE wanes to levels unlikely to reduce transmission within 5-6 months of the second dose. (59, 60)

Booster (three doses)

VE of one booster (three doses) against Omicron infection is 55-69%. (58, 59) The VE against Omicron infection wanes to 50% (95% CI: 46.5; 53.1) after four months for individuals aged 18-59 years. (59)

Second booster (four doses)

VE relative to a first booster dose against Omicron infection is estimated between 30-45% 7-30 days after the second booster. (61, 62) and 33-65% in the period of 2-6 weeks after the second booster. (63, 64)

Two studies estimated a decline in relative VE down to 10-22% from 8-10 weeks after receiving the second booster. (63, 64)

Note: Many countries have only recently began implementing a second booster dose for specific population groups, so data are still emerging about potential benefits and risks. Currently, most studies are in groups that received a second booster first (e.g. elderly and immunocompromised). Additionally, data from studies can be difficult to interpret separately for just ‘Pfizer’ as many studies combine Pfizer and Moderna datasets, as both are mRNA vaccines.

##### VE against symptomatic infection

Primary Course (2 doses)

VE against Omicron variant causing symptomatic has been estimated at 42% (95% CI: 15-60) based on meta-analysis. (65) However, this does not account for time since vaccination.

First booster (three doses)

Two-dose vaccine effectiveness against Omicron variant causing symptomatic infection ihas been estimated at 42% (95% CI: 15-60) based on meta-analysis. (65) However, this does not account for time since vaccination.

Second booster (four doses)

A study on efficacy showed relative VE 7 to 30 days after receiving the second booster dose was approximately 55% (95% CI, 53 to 58) against symptomatic Omicron infection compared to one booster dose. (61)

##### VE against severe disease / hospitalisation

Primary course (2 doses)

Data from multiple countries indicate that vaccine effectiveness is between 62% - 70%, from 2 weeks after receiving the second dose. (60, 66) A US study with mRNA vaccines reported a higher VE of 81%. (67) After 5-6 months the VE declined to 44% (CI 95%, 30-54%) (60), whereas a Danish study reported an VE of 66% after 4 months. (59)

First booster (3 doses)

VE of one booster (three doses) against Omicron related hospitalisation is estimated to be 83%. (58, 68-73)

Data from multiple countries (UK, South Africa, USA, Denmark, and Hong Kong) show high vaccine effectiveness (VE) of 89% - 92% against hospitalisation for people aged 18-59 years >2 weeks after receiving a booster including for those people aged 65 years or older. (59, 66, 67, 74, 75)

After 10 or more weeks the VE against Omicron related severe disease/hospitalisation has been estimated to wane to 75-83%. (74, 75) and further wanes to approximately 50% after >3 months. (66, 67, 76).

Second booster (4 doses)

Compared to people vaccinated with one booster dose of Pfizer, the relative VE against infection of a fourth dose peaks at 64% (62-66%) during the third week (77).

Relative VE against Omicron related severe disease is estimated at between 58% - 77% 2-6 weeks after second booster dose with no signs of waning by the 6th week. (61, 63, 64), increasing to 87% after 7-10 weeks. (64, 77) For people aged 60+ year relative VE peaked after 3-4 weeks at an adjusted rate of 52%. (63)

Adjusted VE against BA.4/5 related hospitalisation is estimated to be 60% (95%CI, 42-73%) up to three months after receiving the second booster and 56% (95% CI, 41-46%) after >3 months. (78)

##### VE against death

Primary course (2 doses)

Qatar: VE against Omicron-related severe, critical or fatal COVID-19 infection for two doses of Pfizer was estimated to be 73.5% (95% CI, 60.5 - 82.2%). (68)

First booster (three doses)

Qatar: relative VE (compared to the primary course) against any severe, critical, or fatal COVID-19 for a Pfizer booster dose was estimated at 100.0% (95% CI: 71.4-100.0). (79)

Hong Kong: relative VE (compared to the primary course) against Omicron (BA.2) related mortality for 20-59 years was 83% (-29-98%), 60-69 years 82% (20-96%), 80+ years 66% (-1.3-89%). (76)

Second booster (four doses)

A study on efficacy indicates that relative VE 14 to 30 days after receiving the second booster dose was 76% against Omicron related death compared to one booster dose. (61)

The relative VE (compared to third dose) of a fourth dose of mRNA vaccine against all-cause mortality in long-term care facilities residents in Sweden declined to 27% 61-126 days post vaccination. (80)

#### World Health Organization review of vaccine efficacy

A WHO weekly epidemiological report (14 August 2022) included an updated summary of evidence on Omicron, including for vaccine effectiveness. (81)

The WHO notes that results of vaccine effectiveness (VE) studies should be interpreted with caution because estimates vary with the type of vaccine administered and the number of doses and scheduling (sequential administration of different vaccines). (81)

Some key points from the WHO interpretation of results of VE for the Omicron variant include:

* To date, 37 studies from 15 countries have assessed the duration of protection of six vaccines against the Omicron variant.
* Findings from these studies show reduced VE of primary vaccine series against the Omicron variant than has been observed for previous variants, for all outcomes (severe disease, symptomatic disease, and infection).
* However, in the majority of studies, VE estimates against the Omicron variant remain higher for severe disease.
* VE estimates against symptomatic disease and infection within the first three months of primary series vaccination tended to be lower than those against severe disease, and VE decreased more substantially over time.
* Booster vaccination substantially improves VE for all outcomes, but studies that assess VE of booster vaccination beyond 6 months are needed to evaluate the duration of protection are not yet available.

### Omicron: Immunological response to vaccination

*Section updated: 27 September 2022*

#### Immunological response to vaccine in adults, T-cells & B cells

A longitudinal study in vaccinated UK health care workers showed that immune response varies based on previous infection and vaccination. (82)

* The study found that different infection histories alongside different timings of vaccination had an impact on immune response against Omicron.
* The study results most relevant to the New Zealand population (vaccinated, and either infection naïve or post-Omicron infection) were that Omicron infection in vaccinated people resulted in some enhancement of neutralising antibody and T-cell response against Omicron, but this enhancement was less than that observed against earlier variants (Alpha and Delta).
* The study cohort contained only vaccinated participants, so the magnitude of immune response to Omicron infection could not be compared to the response in people naïve to any SARS-CoV-2 antigen exposure.
* The study investigators hypothesise that previous order of exposure to SARS-CoV-2 antigens (through vaccination or infection) results in immune imprinting, which affects response to subsequent SARS-CoV-2 exposures.

##### Neutralising antibody (nAb)

Neutralisation studies provided initial data predicting lower vaccine effectiveness against Omicron (BA.1) than for previous variants. (83-88) BA.2 does not appear to have a greater capacity for immune evasion by antibody neutralisation than BA.1. (89-91)These data have now been superseded by effectiveness data.

Neutralising antibody against BA.5

Neutralisation titres from studies suggest that vaccine-induced neutralising antibody levels against BA.4 and BA.5 are lower than against BA.1 and BA.2 in serum from triple dosed vaccinated individuals, but data remain limited: (23, 92) One study compared the neutralisation of BA.4/5 28 days after a third dose of Pfizer (BNT162b2) and found antibody titres were reduced 3.2-fold compared to both BA.1 and BA.2. (23)

A follow-up study of 700 participants who received a second booster of Pfizer (four months after first booster) found a 26% multiplicative decay per week of neutralising antibodies and 14% of immunoglobulin G (IgG). (93) A pre-print (July 2022) compared the levels of neutralisation titres of antibodies against SARS-CoV-2 variants after three and four doses of vaccination of Pfizer or Moderna. (94) In this study a fourth dose increased neuralisation titres by 5.6-fold against BA.4/BA.5 compared to levels after a third dose only. However, even after the fourth dose, the titres were significantly decreased against BA.4/BA.5 compared to against BA.2 and the original Wuhan variants which were 2.5-fold and 16.4-higher respectively.

It is not yet clear how these neutralising antibody levels relate to vaccine efficacy (i.e. there is no established correlate of protection).

Analysis of whole-blood samples of 100 volunteers confirms that boosters can achieve higher levels of nAb blocking (blocking activity of a sample against the binding of the viral spike protein to the human receptor) against VOCs than that achieved by the initial two-dose vaccination. (95) There is significant variability in the percentage of nAb blocking against Omicron infection from after two doses of mRNA vaccine, with a range of 0.0% to 39.4%. The nAb blocking increased to a median of 88.1% one month after the first booster and waned to a median of 70.7% (CI: 95%, 66.4-82.8%) after three months. (95)

This shows that the booster can achieve higher levels of nAb blocking of VOCs than that achieved by the initial two-dose vaccination. (95) However, fast waning of nAb tires compared with the wild type (WT) or Delta, suggest that long-lasting nAb response against more immunologically diverse VOCs may be difficult to achieve while boosting with the current mRNA vaccines based on the WT virus. (95)

**Vaccination and breakthrough infection**

Neutralising-antibody (nAb) titres after an mRNA booster against all Omicron subvariants waned more substantially in those participants who did not have breakthrough infections than in those who had a breakthrough infection. (96) A longitudinal cohort of health care workers from Ohio State University who received three doses of mRNA vaccine (Moderna and Pfizer) showed that neutralising-antibody titres against BA.4/5 waned at a 30-day decay rate of 19.55% for the ‘vaccination only group’, compared to 12.12% for those with three doses and a previous SARS-CoV-2 infection, indicating lower durability of protection for boosted, infection naive people. (96)

Similarly, SARS-CoV-2 infection after vaccination was found to boost the neutralising antibody response compared to vaccination alone. (97) A longitudinal cohort study of 110 participants found that vaccinated participants (2-4 doses of mRNA vaccine) recovered from infection have higher spike specific IgG and RBD antibody levels compared to infection-naive group’. (97)

##### Cell-mediated responses

While data remain preliminary, an increasing number of studies indicate that vaccination provides a durable T-cell response to Omicron infection. (92)

##### Immunopathological characteristics

Omicron breakthrough patients had a more robust IFN-y response (critical for viral clearance) and lower concentration of proinflammatory cytokines at the acute phase of infection. They also had lower frequency of immature neutrophils indicating milder inflammatory response. (98) It has been reported that BA.4/BA.5 has an increased ACE2 affinity compared to other variants (Wuhan, BA.1 and BA.2). This likely causes an increased binding half-life, which may contribute to the growth advantage of BA.4/BA.5 by enhancing cell entry. (23)

### Omicron: Reinfection

*Section updated: 27 September 2022*

##### Reinfection after previous infection with a “pre-Omicron” variant

* Several studies have estimated the effectiveness of previous infection with a pre-Omicron variant (e.g. Delta) against reinfection with Omicron. Effectiveness estimates range from 15% to 61.9% (18, 60, 99, 100), but it is often unclear in studies when the previous infection occurred relative to the study period, making is difficult whether this variability is due to waning of effect. Effectiveness against hospitalisation/death was 87.8%. (101, 102)
* A study using Johns Hopkins SARS-CoV-2 genomic surveillance data from March 2020 and July 2022 found that a majority of observed reinfections (95%) were caused by the Omicron variant and reinfection can occur in vaccinated and immunocompetent people. (103) While over 90% of infections were symptomatic, only 4% of cases were hospitalised which indicates that confirmed reinfections increased with the Omicron variant but were generally associated with mild infections. (103)

##### Reinfection after previous Omicron infection

* Infection with previous Omicron variants provides protection against subsequent Omicron Infection. Previous Omicron infections is estimated to provide between 76% and 94% protection against symptomatic BA.4/5 infection (time period not reported, but likely within 3 to 5 months since previous infection). (17, 18)
  + A study in Qatar (conducted approximately 5 months after first Omicron wave (104)) estimated the effectiveness of a previous Omicron infection against symptomatic BA.4/BA.5 reinfection was 76.1% (95% CI: 54.9-87.3%), and against any BA.4/BA.5 reinfection was 79.7% (95% CI: 74.3-83.9%).(18)
  + A Danish study (conducted approximately 3 months after first Omicron wave (104)) estimated the effectiveness of a previous Omicron infection on BA.5 infection among triple-vaccinated individuals.(17) Prior omicron infection was highly protective against BA.5 (94%, 95%CI 92-95).(17)

## Disease course

### Viral dynamics

*Section updated: 27 September 2022*

##### Median or mean incubation period 3-4 days, maximum incubation unclear (6-8 days reported). Omicron may have a shorter serial interval than Delta.

##### Incubation period -The time from infection until symptoms develop

* A systematic review and meta-analysis assessing the incubation period associated with different SARS-CoV-2 variants was published in August 2022. The mean incubation period for COVID-19 cases caused by the omicron variant was 3.42 days (95% CI, 2.88-3.96 days), based on 5 studies with a total of 829 patients. (105) This is shorter than the Alpha, Beta, and Delta variants.
* A German Study (August 2022) has reported a decreased interval between onset of symptoms in the primary and secondary cases in a household for Omicron compared to preceding variants.(106) For Omicron, there was an average of 3.85 days between symptom onset compared to 4.8 with WT. See table below. (106)




Table 1: Mean time from symptom onset of primary case in households and symptom onset of secondary case, by variant; Germany, 2020-2022.

Single exposure event data (assumes participants infected at event):

* Incubation periods are short, ranging from 0 to 8 days, with a mean or median incubation period of around 3 days (107-110)

Human challenge studies (non-Omicron, novel transmission data)

* Incubation period of 2 to 4 days after inoculation with **wild-type virus.** (57) Viral load (VL) rose steeply and peaked around day 4-5.

##### Serial Interval - The time from infection in one person to infection in the next person

* The mean serial interval ranges from 2.5 to 4.8 days. (52, 110-112)

##### Latent period - The time from infection until the case becomes infectious

Human challenge studies (non- omicron, novel transmission data)

* Viral shedding by qPCR became quantifiable in throat swabs from 40 hours post-inoculation, significantly earlier than in the nose, where initial viral quantifiable detection occurred at 58 hours post-inoculation. (57)

##### Duration of infectiousness

* Studies for several countries (Japan, Switzerland, Singapore) among predominately vaccinated people show that for vaccinated people, viral RNA from Omicron samples was highest 3-6 days after diagnosis or symptom onset and then decreased gradually, with a marked decrease 8-10 days after diagnosis or symptom onset. (98, 113, 114)
* One study found positive viral cultures were obtained from day 2 of infection, but samples obtained on day 5 were negative. (98)

##### Duration of illness

* Time to resolution of symptoms varies. In one small study, 21 of 33 attendees at a gathering tested positive soon after. At the end of follow-up (12-14 days after exposure event), five individuals still reported symptoms, while the rest (16 individuals) reported symptoms lasting 1 to 9 days. (107)
* A study based on data from the UK ZOE COVID app found that the duration of acute symptoms was shorter during Omicron prevalence than during Delta prevalence, with the average presentation of Omicron being 2 days shorter than that of Delta. (115)
* A recent study describing a cross-sectional survey in Israel found that among 199 young, healthy, and mostly vaccinated soldiers, the median time of symptom resolution was 4 days. (116)

### Symptomatology

*Section updated: 27 September 2022*

#### Asymptomatic Disease

* Data suggests a substantial proportion of Omicron cases may be asymptomatic – estimates range from 25-54%. (60, 117)
  + UK data reported from the Real-time Assessment of Community Transmission-1 (REACT-1) survey (Round 17; 99% Omicron cases) found a substantial proportion (approximately 25%) of positive tests were in asymptomatic people. (118) Of note, the vaccine status of individuals within this group was not included in the report.
  + A study from Korea investigated the clinical and epidemiological characteristics of 40 patients with Omicron (42.5% were fully vaccinated) and found that half of the patients (19, 47.5%) were asymptomatic, while the others had mild symptoms. (119)

#### Symptoms of Omicron

##### Upper Respiratory Tract Symptoms

* Upper respiratory symptoms predominate in most individuals. The most common symptoms reported are: cough; runny/stuffy nose; fever; muscle pain; fatigue; headache and sneezing.(108, 120-123) The COVID Symptoms Study reports that headache and sneezing are also common symptoms of Omicron infection. (123) A study from Japan reported that cough (47.3%) and sore throat (32.9%) were the most common COVID-19 related symptoms in the early phase of SARS-CoV-2 infection during the Omicron variant wave. (124)
* A sore throat has been reported more in Omicron cases than Delta, with reports ranging from 25% - 53% of cases. (98, 119, 125) UKHSA states that the findings relating to reports of sore throat could be incidental and suggests that sore throat may not be a specific predictor of Omicron infection, as another recent study led by Oxford University and the Office for National Statistics (126) found increased reports of sore throat in both PCR-positives and symptomatic PCR-negative cases. More data are required to understand which symptoms may be used to identify Omicron infections.
* Loss of taste and smell has been reported less in Omicron cases than Delta, (60, 125) with the UKHSA reporting 13% of Omicron cases compared to 34% of Delta cases.(60, 125) In a large UK study drawing on data from the ZOE app (matched for age, sex and vaccination dose), loss of smell was less common in participants infected during a period of Omicron prevalence than during Delta (16·7% vs 52·7%, odds ratio [OR] 0·17; 95% CI 0·16–0·19, p<0·001). (115)

##### Lower Respiratory Tract Symptoms

* There appears to be less involvement of the lower respiratory tract associated with Omicron infection compared to Delta. (115)
* A study from Canada of 1,063 cases of Omicron (confirmed or suspected) found that only 10% reported shortness of breath. (122) Similarly, in a study conducted in Japan during the B.1.1.529 Omicron variant wave between January and May 2022, 9.9% of participants who tested positive reported dyspnoea. (124)
* Omicron cases have been reported as less likely to develop pneumonia (3.4 vs 16.1%, p=0.005). (98)

##### Symptoms in Children

* Symptoms reported in paediatric cases in South Africa have included fever, vomiting, diarrhoea and convulsions. (127)

##### Effect of vaccination on symptomatology

* Data suggests no difference in symptoms between vaccinated and unvaccinated cases of COVID-19 infection but milder and of shorter duration in vaccinated cases (data likely to include both Omicron and Delta cases). ([link](https://health-study.joinzoe.com/blog/covid-new-top-5-covid-symptoms))

|  |  |  |
| --- | --- | --- |
| **Symptoms** | **Percentage of people with this symptom**  **within 35 days of a positive PCR,**  **among those people with a Ct value under 30** | |
| **January 2022** | **May 2022** |
| **Any symptoms** | 61.27 | 59.71 |
| **No symptoms (asymptomatic)** | 38.73 | 40.29 |
| **Classic symptoms (cough, fever, shortness of breath, loss of taste, loss of smell)** | 49.46 | 51.73 |
| **Loss of taste or smell** | 11.1 | 11.89 |
| **Gastrointestinal symptoms (abdominal pain, nausea or vomiting, diarrhoea)** | 14.46 | 13.9 |
| **Cough** | 40.49 | 46.34 |
| **Fatigue (weakness)** | 34.13 | 37.14 |
| **Headache** | 36.63 | 34.54 |
| **Sore throat** | 35.71 | 37.64 |
| **Fever** | 21.12 | 22.77 |
| **Loss of smell** | 7.58 | 8.01 |
| **Muscle ache (myalgia)** | 23.25 | 22.82 |
| **Loss of taste** | 9.14 | 9.6 |
| **Shortness of breath** | 11.53 | 11.19 |
| **Nausea or vomiting** | 8.19 | 7.7 |
| **Abdominal pain** | 6.23 | 4.66 |
| **Diarrhoea** | 5.46 | 6.39 |

The above table is taken from the 22 June 2022 edition of UK COVID-19 Infection Survey. (128)

#### Severity

Overall, Omicron appears to be associated with a milder course of illness and more favourable outcomes compared to previous variants.

* The WHO carried out a large analysis of South African data, comparing the clinical severity and outcomes between 17,693 hospitalised patients during the ‘Omicron period’ compared with 16,749 patients during the ‘Delta period’. (129) Their analysis suggests evidence of reduced severity and lower mortality for the Omicron variant compared to Delta. 28.1% of Omicron patients had severe disease, compared with 49.2% of the Delta patients. 3.7% of the Omicron cohort and 7.7% of the Delta cohort had critical disease. In an adjusted analysis, Omicron was associated with a lower odds of developing severe or critical disease (OR: 0.43; 95% CI: 0.41–0.46 and p < 0.001) compared to Delta. Additionally, Omicron was associated with lower risk of in-hospital mortality. However, the WHO cautions that their analysis should not be seen as supporting the ‘mild variant’ narrative.
* A retrospective cohort study SARS-CoV-2 infection which included 118,078 persons with COVID-19 in California found that infection with the Omicron variant was associated with approximately 50% lower risk of severe clinical outcomes compared to the Delta variant. (130)

#### BA.4/BA.5-specific clinical features (symptoms and severity) information

The BA.4/5 wave has been associated with a rise in hospitalisation both internationally and in New Zealand. While an increase in the number of cases has been demonstrated, there has been little evidence to support a significant change in severity compared to the previous predominant mutation, BA.2. (131-133)

* UK, US, Portugal, China and many more countries reported a steady increase in hospitalisations and deaths from May 2022 to July 2022, aligning with the BA.5 wave. (134, 135)
* On 22 July 2022, the [CDC](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html) reported that hospitalisation rates in the US were rising due BA.5 infections. This variant accounted for 78% on infections, which rose from 550 hospitalisations per day at the end of May to over 2200 per day in the second week of July. This has since started to drop. (136)
* South Africa reported a similar rate in hospitalisation due to BA.4/BA.5 and BA.1. (133)

### Hospitalisation

#### Hospitalisation frequency for Omicron relative to Delta

Adjusted for vaccination status (important for understanding basic differences in severity as it can remove differences in vaccine effectiveness from assessment, though residual confounding for vaccination status may still occur):

* Risk of hospitalisation/severe disease was found to be lower for Omicron than Delta in multiple countries (Sweden, Norway, the US, France, Scotland[[4]](#footnote-5), the UK, Canada[[5]](#footnote-6), Portugal), with estimates ranging from 40-73%. (137-147)
* A study from South Africa showed that much of the severity reduction observed for Omicron relative to Delta was due to prior infection and vaccination. Intrinsically reduced virulence accounted for a ~25% reduced risk of hospitalisation/death compared to Delta. (148)
* A large study using data from Spain included 48,874 cases during the delta period and 560,658 during the Omicron period. (149) During the Delta period, on average, 3.8% of the detected cases required hospitalization for COVID-19. This percentage dropped to 0.9% with omicron [RR of 0.46 (95% CI: 0.43 to 0.49)].
* However, a US study found a relative increase in emergency department visits (86%) and hospitalisations (76%) from Omicron compared to the Delta period, though this was due to the higher volume of cases and there was a relative decease in the length of stay in hospitals (-27%). (150)
* Danish data (151) stratified rather than adjusted by vaccination status:
  + Among those with <2 doses: 43% lower risk of hospitalisation
  + Among those with 2 doses: 29% lower risk of hospitalisation
  + Among those with 3 doses: 50% lower risk of hospitalisation
* Unadjusted for vaccination status (provides indication of burden on healthcare at the level of vaccination in country where study conducted):
  + Reduction in hospitalisation of 38% for emergency department attendance or admission, and 62% for admission (54)
  + Reductions in hospitalisation compared to Delta range from 36% to 53% depending on country. (151-153)

#### Paediatric hospitalisation

* Both the UK and South Africa saw a rapid increases in paediatric COVID-19 cases and hospitalisations in late 2021, mirroring high community transmission of the Omicron variant, with the UK seeing a 3-fold increase in 2 weeks. (60, 127)
* In the UK, the most rapid rise was among children under 5 years, however some small reviews of Omicron admissions in infants found those admitted were not severely unwell, and less severe than previous waves. (60, 154, 155)
* A US study of children under 5 years found a significantly lower risk for severe clinical outcomes in the 3-day time-window following initial Omicron infection compared to Delta. (156) Risk for an ED visit was 18.83% (vs 26.67%), hospitalisation was 1.04% (vs 3.14%), ICU admissions was 0.14% (vs 0.43%), and mechanical ventilation was 0.33% (vs 1.15%).
* Another US study found during the Omicron wave, paediatric acute upper airway infections have increased with more developing severe disease, suggesting Omicron replicates more efficiently in the conducting airways. (157)
* Although Omicron infections have led to a rise in hospitalisation rate in under 5-year-olds, there has been an estimated 1/3 reduction in hospitalisation rate of over 12-year-olds. The study however, did not assess severity of hospitalised cases. (158)

#### Risk factors for hospitalisation with Omicron

* A UK study found the age range of individuals admitted with Omicron to 29 December 2021 was 0 to 100 years (median: 45.5 years); 496 (60.9%) were aged 40 years or more; 30.8% were aged 70 years or more. (143)
* Public Health Scotland data reported on hospital admissions for COVID-19 (week of 22-28 December 2021) shows approximately 44% were in people 60 plus years of age, and 21% of admissions were in people aged 80 plus. (159)
  + Most cases of COVID-19 at this time in Scotland were Omicron but the proportion of cases of the Omicron variant for each age-group hospitalised are not reported.

#### Time to hospitalisation with Omicron

Currently, there are no studies to date that have investigated this.

#### Time in hospital with Omicron

* Hospital stays from Omicron infection range from 1 to 6 days. This varies depending on country and demographic but the mean time in hospital tends to be 3 to 4 days. (47, 152, 160) Overall, hospital stays for Omicron infections are significantly shorter compared to that of Delta infections. (144, 145, 161)

### ICU admission

#### Severe/ICU/ventilated frequency

* ICU admission from Omicron infection is around 70-74% lower than from Delta infection. (144, 152)
* In a large Spanish study, the risk of ICU admission dropped from 0.8% of detected cases during Delta predominance, to 0.1% during Omicron predominance [RR 0.25 (95% CI: 0.21 to 0.28)]. (149)
* South African data: Among *hospitalised* individuals, after controlling for factors associated with severe disease[[6]](#footnote-7), the odds of severe disease did not differ between S-Gene Target-Failure (SGTF, interpreted as Omicron) infected individuals compared to non-SGTF individuals diagnosed during the same time period (aOR 0.7, 95% CI 0.3-1.4). (162) Compared to earlier Delta infections, after controlling for factors associated with severe disease[[7]](#footnote-8), SGTF-infected individuals had lower odds of severe disease (aOR 0.3, 95% CI 0.2-0.5).
* The risk of needing ventilatory support among patients with Omicron infection is significantly lower than for Delta. (47, 152, 160)

### Death

#### Death frequency for Omicron relative to Delta

Studies have found a 73-86% reduction in death relative to Delta, however, the extent of the reduction was attenuated when prior infections and vaccination are also considered. (148)

* In South Africa, the Hazard Ratio was 0.72, and an adjusted reduction to relative risk to Delta was 28%. (148)
* In a WHO analysis of South African data, 15% of hospitalised Omicron patients died. (129)
* The odds of death in a Portugal study were 0.14 (95% CI: 0.0011-1.12), representing a reduction in the risk of death of 86% for Omicron compared with Delta. (145)
* US: Unadjusted hazard ratios for mortality associated with Omicron variant infection was 0.09 (95% CI : 0.01-0.75)(152) but unadjusted ratios could be confounded by many factors, and the short follow up time might bias results.
* UK data in long term care facility residents: Reduced risk of death within 28 days of a new diagnosis in the Omicron dominant period (1.1 deaths / 1000 person-days, 95% CI: 0.6-2.2) compared to the pre-Omicron period (3.8 deaths / 1000 person-days, 95% CI: 2.8-5.2).(146)

#### Time to death

UK data: median time from Omicron specimen date to death was 5 days (range 0 to 14). (143) Note that specimen date might not reflect date of symptom onset.

## Therapeutics

*Section updated: 27 September 2022*

#### Therapeutic use for treatment of COVID-19

* Most people can safely manage their own COVID-19 symptoms at home. However, for people with risk factors for severity or comorbidities, different therapeutic options may provide improved outcomes for the patient.
* The Ministry of Health has an overview [about COVID-19 therapeutics](https://www.health.govt.nz/covid-19-novel-coronavirus/covid-19-health-advice-public/about-covid-19/about-covid-19-therapeutics) and [advice for healthcare professionals](https://www.health.govt.nz/covid-19-novel-coronavirus/covid-19-information-health-professionals/covid-19-advice-all-health-professionals#adult-management) websites.
* Therapeutic options currently include antiviral medications (Paxlovid, remdesivir, molnupiravir), anti-SARS-CoV-2 monoclonal antibodies (Evusheld, sotrovimab), immunomodulators (baracitinib, tocilizumab) and anti-inflammatory drugs (dexamethasone, budesonide) available as EUA for COVID-19 management. (163) The utility, effectiveness and need for each of these options is different between individuals, and criteria for each is specific, based on disease severity and individual risk factors.
* The emergence of new variants produces challenges to the therapeutics as adaptive mutations can completely alter the viral genome and pathogenic potential. New variants that become VOC are often associated with increased virulence, pathogenicity and transmissibility which may help them evade the immune response and have decreased response to current therapeutics. (22, 163)

#### Therapeutics in relation to BA.4 and BA.5

* Many monoclonal antibodies showed reduced efficacy against Omicron variants relative to Delta. (164)
* Additionally, although many of the newer Omicron subvariants are derived from BA.2, there are significant mutations in the spike protein. (22) It has been established that this reduces the sensitivity to vaccine-induced neutralising antibodies. (165, 166) As a result, it becomes likely that these variants will also have reduced sensitivity to therapeutic monoclonal antibodies. (22)
* Evusheld is a long-acting antibody combination (tixagevimab and cilgavimab) derived from the B cells of individuals previously infected by SARS-CoV-2. There are conflicting data supporting its effectiveness against BA.4/5.
  + A [press release](https://www.astrazeneca.com/media-centre/medical-releases/evusheld-long-acting-antibody-combination-retains-neutralising-activity-omicron-variants-ba4-ba5-according-new-study-university-oxford.html) by AstraZeneca (who manufacture the drug) reports data from multiple sources showing neutralising activity against BA.2, the global dominant variant currently, and all other variants tested to date (May, 2022). One study, (23) based at the University of Oxford, has *in vitro* data showing that Evusheld retains neutralisation efficacy against Omicron variants including BA.4 and BA.5.
  + In contrast, another study reported that BA.4/5 showed an increased resistance to Evusheld compared to the BA.2 variant. This was estimated to be a decreased neutralization of approximately 20-fold.(22)
  + Real-world evidence has indicated that Evusheld, when given to vaccinated people, provides an increased protection against symptomatic and severe COVID-19 compared to booster vaccination alone. (24)
  + Two pre-prints have assessed the neutralizing abilities against Omicron variants and reported that Evusheld has markedly reduced potency against the emerging Omicron sub lineage BA.4.6 in *in vitro* studies. (6, 7)
    - The BA.4.6 variant appears to make up a relatively low proportion of cases globally, with a small amount of growth advantage reported. This appears to be resulting in a ‘slow’ creep in growth rather than becoming quickly dominant. (9)
    - BA.4.6 only represents 3% of all domestic cases that have undergone WGS, and this number has remained relatively consistent over the past month making it still an effective therapeutic where indicated. (8)
    - This suggests that Evusheld is likely to retain a high efficacy for over 95% of COVID-19 cases, as global prevalence of BA.4.6 remains low.
* A preprint study suggested that among the therapeutic antibodies authorized for clinical use, only bebtelovimab (LY-COV1404) retains full potency against both BA.2.12.1 and BA.4 and BA.5.(167)
* Research published in the New England Journal of Medicine reports that three antivirals (Paxlovid, molnupiravir, and remdesivir) retain efficacy against the dominant Omicron sublineages BA.5 and BA.2.75. (5)

#### Rebound after therapeutics

“Rebound” (the return of COVID-19 symptoms after an infected person has finished medication) has been reported after use of both Paxlovid and molnupiravir. (168, 169)

* A pre-print, using data collected in the USA during Omicron dominance (January to June 2022) has reported on three types of rebound associated outcomes: COVID-19 infection (coded as lab-test confirmed presence of “SARS coronavirus 2 and related RNA”), symptomatic COVID-19, and COVID-19 hospitalisations (169)
* This was reported after seven and 30 days for Paxlovid and molnupiravir. The percentage of rebound for each outcome is captured in the table below.

|  |  |  |  |
| --- | --- | --- | --- |
| Time after Treatment | Rebound Infection Severity | Paxlovid | Molnupiravir |
| 7 days | COVID infection | 3.53% | 5.86% |
| Symptomatic COVID-19 | 2.31% | 3.75% |
| COVID-19 Hospitalisations | 0.44% | 0.84% |
| 30 days | COVID infection | 5.40% | 8.59% |
| Symptomatic COVID-19 | 5.87% | 8.21% |
| COVID-19 Hospitalisations | 0.77% | 1.39% |

* The low rates of hospitalisation reported above suggest that rebound infections are generally not severe. Therefore, the study speculates that treatment with a further antiviral course is might not be beneficial.
* Additionally, the difference between COVID-19 hospitalisation after Paxlovid and molnupiravir treatment was not found to be statistically significantly different. However, the cohort treated with Paxlovid were younger than the molnupiravir treated cohort (average age of 56 vs. 62 years, respectively) which may account for the slightly lower rate of hospitalisation.
* One limitation of the report was that the severity of the initial infection was not reported.

Rebound infections after the use of oral antivirals has indicated that the broad administration of stand-alone therapeutics may not be the most effective treatment against SARS-CoV-2. The use of multiple agents with different mechanisms of action, as in the modern treatment of HIV may be necessary to maximise the longevity of therapeutic. (168)

Pfizer have [initiated a Phase II trial](https://www.fiercepharma.com/pharma/fda-wants-pfizer-study-covid-rebound-effect-longer-course-paxlovid) testing Paxlovid in immunocompromised patients. The trial will compare 5-, 10-, and 15-day courses of the oral antiviral to investigate the effect of longer dosing in reducing the incidence of rebound infections. Results from this study are expected September 2023.

## Detection

### PCR

*Section updated: 16 May 2022*

**Most observational studies have relied on SGTF as a proxy for Omicron, which identifies BA.1 but not BA.2. Therefore, caution is required when interpreting comparative analyses which use S-gene target results as the only determinant of Omicron and Delta.**

BA.2 lineage generally does not have the spike deletion at 69-70 that causes S-gene target failure (SGTF). (143) It is nicknamed the “stealth” version of Omicron as it cannot be detected using PCR tests that detect SGTF ([link](https://www.theguardian.com/world/2021/dec/07/scientists-find-stealth-version-of-omicron-not-identifiable-with-pcr-test-covid-variant))

This has implications on using PCR tests that detect SGTF as a proxy for rapidly detecting Omicron cases.  It should be noted that as at 30 March 2022, the UKHSA reported that 0.16% of BA.2 samples sequenced had the deletion at position 69-70. (170)

### Rapid Antigen Tests (RATs)

*Section updated: 27 September 2022*

PCR testing remains the gold standard for SARS-CoV-2 diagnostics, however the longer turnaround time and restricted use in laboratory settings is unsuitable for large scale testing. Rapid antigen tests (RATs) are now the primary diagnostic tool in New Zealand, due to their fast turnaround time, lack of specialist equipment and ability to be self-administered from home.

The performance of a RAT is generally measured against two outputs, sensitivity and specificity. These are defined as the following:

* sensitivity: a measure of how well the test identifies true positives (i.e., result is identified by test as positive and are positive)
* specificity: a measure of how well the test identifies true negatives (i.e., result is identified by test as negative and are negative).

Aotearoa New Zealand has [approved a number of point of care test (POCT) devices](https://www.health.govt.nz/covid-19-novel-coronavirus/covid-19-health-advice-public/covid-19-testing/rapid-antigen-testing-rat#regulatory). were approved based on clinical performance study design and results that meets the following thresholds:

* Overall ≥80% sensitivity and >98% specificity (recommended by WHO, ECDC, TGA, and European Commission MDCG) compared to the gold standard RT PCR    
  Or
* ≥90% sensitivity for Ct values <25

**Detection of Omicron by Rapid Antigen Tests**

Accurate diagnostic tools are essential in pandemic management, however reliably detecting emerging variants is a challenge. Many of the RATs were developed prior to the emergence of new variants and are based on the reference sequence of the 2019 Wuhan-hu-1 virus. (104) Although nucleocapsid proteins are the most common antigen detected by RAT devices, (104) the spike protein receptor is also a common target for detection. (163) New variants have increasing numbers of mutations in the nucleocapsid proteins and spike protein regions which may limit the reliability of diagnostic tools. (104)

The [FDA](https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests#omicronvariantimpact) has cautioned that RAT devices may have reduced sensitivity to Omicron since its emergence towards the end of 2021. However, it should be noted that it is challenging to compare across studies given that the initial data on RAT performance were collected in clinical settings by healthcare workers, and as such real-world data may not match the reported performance. Sensitivity is also highly variable between different RATs and is strongly correlated with viral load and symptomatology.

For many RATs, the sensitivity was above 80% when initially tested in clinical settings. Studies suggest that sensitivity to Omicron in RAT devices is lower than in previous variants with reported sensitivities ranging from 27.5%-63%. (22, 104, 164) However, this data is currently limited due to issues with comparability across studies, settings and devices. Currently there is some emerging evidence that suggests a clinically relevant decrease in the performance of RATs for detection of the Omicron variant. (10, 11) Comparability between studies is limited by difference in study design and objectives. For these reasons it is difficult to compare the results between studies and evidence of reduced sensitivity may not be indicative of device performance.

All RATs available in New Zealand have been and will continue to be screened for acceptable performance. RATs are still recommended as the best method of POCT in New Zealand however, test performance will require ongoing review as new variants arise. (171)

Emerging evidence indicates that serial rapid antigen testing may become vital for early detection of new omicron variants. (172) Serial testing is the process where an individual is tested multiple times over a period of a few days to increase the chances of detecting COVID-19 which a single test might have missed. This is commonly used in asymptomatic patients to overcome limitations of poor sensitivity. A recent study showed that serial rapid antigen testing every three days was found to be more effective at case detection than RT-PCR testing. (172) This is due to the rapid turnaround time of RATs compared to PCR tests, enabling rapid isolation and is a lower cost method of case identification. RATs are likely to remain central in testing strategies despite reduced sensitivity to new variants.

# Section 4: Appendices

## Glossary

|  |  |
| --- | --- |
| **AstraZeneca vaccine** | AZD1222 or ChAdOx1 |
| **Pfizer/BioNTech vaccine** | Comirnaty or BNT162b2 |
| **Global Initiative on Sharing Avian Influenza Data (GISAID)** | This is a consortium that promotes and provides open access to SARS-CoV-2 genomic sequence data. Its original purpose was for sharing data on avian (bird) flu. |
| **Immune escape** | The ability of the virus to evade our body’s immune response. See also Immune response. |
| **Immune response** | The response of our immune system to an infection or antigen. It includes development of specific antibodies to the virus and also cell-mediated responses (triggered by T cells). |
| **Mutation** | Small change made to the pattern of nucleotides that make up the virus. These occur as the virus spreads and replicates. Most do not confer a benefit to the virus. |
| **Naming mutations** | Mutation nomenclature (i.e., how they are named), describes what occurred at a specific location of the genome. For example, the ‘E484K’ mutation means that at the position 484, the amino acid changed from glutamic acid (E) to lysine (K). When a deletion occurs, the location is provided (e.g., deletion 144). |
| **N-terminal domain** | Part of the spike protein of the SARS-CoV-2 virus. |
| **R0, Basic Reproductive number** | The basic reproductive number R0 (R-naught), is a measure of how contagious a pathogen is. It is the average number of people who would become infected from one infected individual in a population where everyone is susceptible (that is, a population that has not previously encountered the disease or received vaccination). |
| **Reff, Effective reproductive number** | The ‘effective R’ (Reff) is the average number of secondary cases per infectious case in a population made up of both susceptible and non-susceptible people. . In general, whenever Reff is less than 1(that is, an infected person goes on to infect less than one person on average) then the incidence of the disease would be expected to decrease. |
| **Secondary attack rate** | The probability that infection occurs among a specific group of susceptible people (for example, within a household) after known contact with an infectious person. |
| **Serial interval** | The time from symptom onset of a case to symptom onset in their identified contacts. |
| **SGTF / SGTP** | “The Omicron genome (lineage BA.1) contains the spike deletion at position 69/70 which is associated with S-gene target failure (SGTF) in some widely used PCR tests. Such PCR tests evaluate the presence of 3 SARS-CoV-2 genes: Spike (S), nucleocapsid (N) and ORF1ab. SGTF is defined as a PCR test where the N and ORF1ab genes are detected (with Ct values less than or equal to 30) but the S-gene is not. SGTF patterns can be used to assess the spread of Omicron lineage BA.1. The Omicron lineage BA.2, VOC-22JAN-01, does not generally contain the spike gene deletion and is S-gene target positive (SGTP).”(170) |
| **Variant** | Viruses with mutations are referred to as variants of the original virus. New variants of SARS-CoV-2 have been emerging as the virus has spread and evolved. |
| **Variant of Concern (VOC)** | **WHO definition:** A SARS-CoV-2 variant that meets the definition of a VOI (see below) and, through a comparative assessment, has been demonstrated to be associated with one or more of the following changes at a degree of global public health significance:  Increase in transmissibility or detrimental change in COVID-19 epidemiology; OR  Increase in virulence or change in clinical disease presentation; OR  Decrease in effectiveness of public health and social measures or available diagnostics, vaccines, therapeutics. |
| **Variant of Interest (VOI)** | **WHO definition:** A SARS-CoV-2 variant:  with genetic changes that are predicted or known to affect virus characteristics such as transmissibility, disease severity, immune escape, diagnostic or therapeutic escape; AND  Identified to cause significant community transmission or multiple COVID-19 clusters, in multiple countries with increasing relative prevalence alongside increasing number of cases over time, or other apparent epidemiological impacts to suggest an emerging risk to global public health. |
| **Variant under Investigation (VUI)** | **UKHSA definition:** SARS-CoV-2 variants, if considered to have concerning epidemiological, immunological or pathogenic properties, are raised for formal investigation. At this point they are designated Variant Under Investigation (VUI) with a year, month, and number. Following a risk assessment with the relevant expert committee, they may be designated Variant of Concern (VOC). |

## Abbreviations

**CDC:** Centers for Disease Control and Prevention

**Ct:** Cycle Threshold

**E:** Glutamic Acid

**GISAID:** Global Initiative on Sharing Avian Influenza Data

**ICU:** Intensive Care Unit

**IPC:** Infection Prevention and Control

**L:** Lysine

**mRNA:** messenger RNA

**N:** Nucleocapsid (Protein)

**NPI:** Non-pharmaceutical intervention

**PCR:** Polymerase Chain Reaction

**RBD:** Receptor binding domain (of the virus spike protein)

**RAT:** Rapid Antigen Test

**Reff:** ‘Effective R’, the effective reproductive number

**R0:** *‘R-naught’, the baseline reproductive number*

**RNA:** Ribonucleic Acid

**S:** Spike (Protein)

**UKHSA**: UK Health Security Agency

**UAI:** Upper Airway Infection

**VE:** *Vaccine effectiveness*

**VTG:** Variant Technical Group

**WHO:** World Health Organisation

## Useful Links

|  |  |
| --- | --- |
| US CDC – SARS CoV-2 variant classifications and definitions | [CDC classification of variants](https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v2.full.pdf?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fcases-updates%2Fvariant-surveillance%2Fvariant-info.html) |
| Outbreak Info | [Outbreak Info](https://doi.org/10.1016/S0140-6736(22)00017-4) |
| WHO - Tracking SARS-CoV-2 variants | [WHO Variant Tracking](https://www.nejm.org/doi/full/10.1056/NEJMoa2201688) |
| UK Health Security Agency Technical Briefings (from October 2021 onwards) | [Investigation of SARS-CoV-2 variants: technical briefings](https://www.ecdc.europa.eu/sites/default/files/documents/Communicable-disease-threats-report-13-aug-2022-all-users.pdf) |
| Public Health England Technical Briefings | [Investigation of SARS-CoV-2 variants: technical briefings](https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201) |

# References

1. World Health Organisation (WHO). Weekly epidemiological update on COVID-19: Edition 105 17 August 2022 [Available from: <https://www.who.int/docs/default-source/coronaviruse/situation-reports/20220817_weekly_epi_update_105.pdf?sfvrsn=cfeb4c18_3&download=true>.

2. World Health Organisation (WHO). Weekly epidemiological update on COVID-19 - 7 September 2022 2022 [Available from: <https://www.who.int/docs/default-source/coronaviruse/situation-reports/20220907_weekly_epi_update_108.pdf?sfvrsn=26cbd0d2_3&download=true>.

3. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 45 2022 [Available from: <https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1103869/Technical-Briefing-45-9September2022.pdf>.

4. Tan ST, Kwan AT, Rodríguez-Barraquer I, Singer BJ, Park HJ, Lewnard JA, et al. Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. medRxiv. 2022:2022.08.08.22278547.

5. Takashita E, Yamayoshi S, Fukushi S, Suzuki T, Maeda K, Sakai-Tagawa Y, et al. Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75 2022 [Available from: <https://www.nejm.org/doi/full/10.1056/NEJMc2209952>.

6. Jian F, Yu Y, Song W, Yisimayi A, Yu L, Gao Y, et al. Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants 2022 [2022.08.09.503384]. Available from: <https://www.biorxiv.org/content/biorxiv/early/2022/08/10/2022.08.09.503384.full.pdf>.

7. Wang Q, Li Z, Ho J, Guo Y, Yeh AY, Liu M, et al. Resistance of SARS-CoV-2 Omicron Subvariant BA.4.6 to Antibody Neutralization 2022 [2022.09.05.506628]. Available from: <https://www.biorxiv.org/content/biorxiv/early/2022/09/06/2022.09.05.506628.full.pdf>.

8. ESR. COVID-19 Genomics Insights (CGI) Report #23, 21 September 2022. Unpublished ESR report. [

9. GISAID. GISAID hCoV-19 Analysis Update 13 09 2022 2022 [updated 13 September 2022. Available from: <https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwjenq_61Zf6AhV52nMBHQtwAaEQFnoECAoQAQ&url=https%3A%2F%2Fgisaid.org%2Fhcov-19-analysis-update%2F&usg=AOvVaw2k6rOcqCvUBgAStrfmbguM>.

10. Leuzinger K, Roloff T, Egli A, Hirsch HH. Impact of SARS-CoV-2 Omicron on Rapid Antigen Testing Developed for Early-Pandemic SARS-CoV-2 Variants 2022 [e02006-22]. Available from: <https://journals.asm.org/doi/abs/10.1128/spectrum.02006-22>.

11. Bekliz M, Adea K, Puhach O, Perez-Rodriguez F, Melancia SM, Baggio S, et al. Analytical Sensitivity of Eight Different SARS-CoV-2 Antigen-Detecting Rapid Tests for Omicron-BA.1 Variant 2022 [e00853-22]. Available from: <https://journals.asm.org/doi/abs/10.1128/spectrum.00853-22>.

12. de Ligt J, Geoghegan J, Douglas J, Hadfield J, Ren U, Winter D, et al. COVID-19 Genomics Insight (CGI) Report. No.11, 15th June 2022, Unpublished ESR report. 2022 [

13. Aggarwal A, Akerman A, Milogiannakis V, Silva MR, Walker G, Kidinger A, et al. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern 2022 [Available from: <http://medrxiv.org/content/early/2022/07/10/2022.07.07.22277128.abstract>.

14. Qu P, Faraone J, Evans JP, Zou X, Zheng YM, Carlin C, et al. Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants. N Engl J Med. 2022;386(26):2526-8.

15. Hachmann NP, Miller J, Collier A-rY, Ventura JD, Yu J, Rowe M, et al. Neutralization Escape by the SARS-CoV-2 Omicron Variants BA.2.12.1 and BA.4/BA.5 2022 [Available from: <https://www.medrxiv.org/content/medrxiv/early/2022/05/19/2022.05.16.22275151.full.pdf>.

16. Quandt J, Muik A, Salisch N, Lui BG, Lutz S, Kruger K, et al. Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes. Sci Immunol. 2022:eabq2427.

17. Hansen CH, Friis NU, Bager P, Stegger M, Fonager J, Fomsgaard A, et al. Risk of Reinfection, Vaccine Protection, and Severity of Infection with the BA.5 Omicron Subvariant: A Danish Nation-Wide Population-Based Study 18 July 2022 [Available from: <https://ssrn.com/abstract=4165630>.

18. Altarawneh HN, Chemaitelly H, Ayoub HH, Hasan MR, Coyle P, Yassine HM, et al. Protection of SARS-CoV-2 natural infection against reinfection with the Omicron BA.4 or BA.5 subvariants 2022 [Available from: <https://www.medrxiv.org/content/medrxiv/early/2022/07/12/2022.07.11.22277448.full.pdf>.

19. European Centre for Disease Prevention and Control. Communicable Disease Threats Report: Week 19, 8-14 May 2022 2022 [updated 13 May 2022. Available from: <https://www.ecdc.europa.eu/sites/default/files/documents/Communicable-disease-threats-report-8-May-2022-public.pdf>.

20. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 43 24 June 2022 [Available from: <https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1086494/Technical-Briefing-43-28.06.22.pdf>.

21. Kislaya I, Casaca P, Borges V, Sousa C, Ferreira BI, Fernandes E, et al. SARS-CoV-2 BA.5 vaccine breakthrough risk and severity compared with BA.2: a case-case and cohort study using Electronic Health Records in Portugal 2022 [2022.07.25.22277996]. Available from: <https://www.medrxiv.org/content/medrxiv/early/2022/07/25/2022.07.25.22277996.full.pdf>.

22. Yamasoba D, Kosugi Y, Kimura I, Fujita S, Uriu K, Ito J, et al. Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies 2022 [updated 01 July 2022. 08 June 2022:[942-3]. Available from: <https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00365-6/fulltext>.

23. Tuekprakhon A, Huo J, Nutalai R, Dijokaite-Guraliuc A, Zhou D, Ginn HM, et al. Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum 2022 [2022.05.21.492554]. Available from: <http://biorxiv.org/content/early/2022/05/23/2022.05.21.492554.abstract>.

24. Young-Xu Y, Epstein L, Marconi VC, Davey V, Zwain G, Smith J, et al. Tixagevimab/Cilgavimab for Prevention of COVID-19 during the Omicron Surge: Retrospective Analysis of National VA Electronic Data 2022 [2022.05.28.22275716]. Available from: <https://www.medrxiv.org/content/medrxiv/early/2022/05/29/2022.05.28.22275716.full.pdf>.

25. Cao Y, Yu Y, Song W, Jian F, Yisimayi A, Yue C, et al. Neutralizing antibody evasion and receptor binding features of SARS-CoV-2 Omicron BA.2.75 2022 [2022.07.18.500332]. Available from: <https://www.biorxiv.org/content/biorxiv/early/2022/07/19/2022.07.18.500332.full.pdf>.

26. Sheward DJ, Kim C, Fischbach J, Muschiol S, Ehling RA, Björkström NK, et al. Evasion of neutralizing antibodies by Omicron sublineage BA.2.75 2022 [2022.07.19.500716]. Available from: <https://www.biorxiv.org/content/biorxiv/early/2022/07/20/2022.07.19.500716.full.pdf>.

27. Wang Q, Iketani S, Li Z, Guo Y, Yeh AY, Liu M, et al. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75 2022 [2022.07.31.502235]. Available from: <https://www.biorxiv.org/content/biorxiv/early/2022/08/01/2022.07.31.502235.full.pdf>.

28. Gruell H, Vanshylla K, Tober-Lau P, Hillus D, Sander LE, Kurth F, et al. Neutralization sensitivity of the SARS-CoV-2 Omicron BA.2.75 sublineage 2022 [2022.08.04.502609]. Available from: <https://www.biorxiv.org/content/biorxiv/early/2022/08/04/2022.08.04.502609.full.pdf>.

29. Qu P, Evans JP, Zheng Y-M, Carlin C, Saif LJ, Oltz EM, et al. Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant 2022 [2022.08.14.503921]. Available from: <https://www.biorxiv.org/content/biorxiv/early/2022/08/15/2022.08.14.503921.full.pdf>.

30. Saito A, Tamura T, Zahradnik J, Deguchi S, Tabata K, Kimura I, et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2.75. bioRxiv. 2022:2022.08.07.503115.

31. Centers for Disease Control and Prevention (CDC). COVID Data Tracker: Variant Proportions 2022 [Available from: <https://covid.cdc.gov/covid-data-tracker/#variant-proportions>.

32. GitHub. BA.2.10(.1) sublineage with S:V83A, H146Q, Q183E, V213E, G339H, R346T, L368I, V445P, G446S, V483A, F490V, G798D, S1003I (11 seq, West Bengal and 1 in New York) 2022 [Available from: <https://github.com/cov-lineages/pango-designation/issues/915>.

33. Stanway D. Shanghai identifies new COVID Omicron subvariant Reuters2022 [updated 10 July 2022; cited 2022 19 July]. Available from: <https://www.reuters.com/world/china/chinas-shanghai-says-new-omicron-subvariant-found-2022-07-10/?taid=62cada3bb77d0e00013570cf&utm_campaign=trueAnthem%3A%2BTrending%2BContent&utm_medium=trueAnthem&utm_source=twitter>.

34. European Centre for Disease Prevention and Control. Changes to list of SARS-CoV-2 variants of concern, variants of interest, and variants under monitoring 07 July 2022 [Available from: <https://www.ecdc.europa.eu/sites/default/files/documents/Variants-page-change-log-07-07-2022.pdf>.

35. Geddes L. Five things we’ve learned about the BA.4 and BA.5 Omicron variants: VaccinesWork; 2022 [updated 12 May 2022. Available from: <https://www.gavi.org/vaccineswork/five-things-weve-learned-about-ba4-and-ba5-omicron-variants>.

36. European Centre for Disease Prevention and Control. SARS-CoV-2 variants of concern as of 12 May 2022 2022 [updated 13 May 2022. Available from: <https://www.ecdc.europa.eu/en/covid-19/variants-concern>.

37. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 44 20 July 2022 [Available from: <https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1093275/covid-technical-briefing-44-22-july-2022.pdf>.

38. World Health Organization (WHO). COVID-19 Weekly Epidemiological Update 29 March 2022: World Health Organization; 2022 [updated 29 March 2022. Available from: <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---29-march-2022>.

39. World Health Organisation (WHO). COVID-19 Weekly Epidemiological Update: Edition 87, published 12 April 2022 2022 [updated 12 April 2022. 87:[Available from: <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---12-april-2022>.

40. GitHub. BE.1.1.1 sublineage with Orf1b:Y264H and S:N460K ( 69 sequences ) emerged in Nigeria ( 14 seqs ) #993 2022 [Available from: <https://github.com/cov-lineages/pango-designation/issues/993>.

41. Cao Y, Jian F, Wang J, Yu Y, Song W, Yisimayi A, et al. Imprinted SARS-CoV-2 humoral immunity induces converging Omicron RBD evolution. bioRxiv. 2022:2022.09.15.507787.

42. Github. BA.2.3 Sublineage with 10 highly convergent S1 mutations (5 seqs, 3xSingapore, 1xAustralia, 1xUSA) #1013 2022 [Available from: <https://github.com/cov-lineages/pango-designation/issues/1013>.

43. University of Edinburgh, Centre for Genomic Pathogen Surveillance, University of Oxford, bluedot, University of Cambridge, University of Sydney. Lineage list [Available from: <https://cov-lineages.org/lineage_list.html>.

44. Sheward DJ, Kim C, Fischbach J, Muschiol S, Ehling RA, Björkström NK, et al. Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies. bioRxiv. 2022:2022.09.16.508299.

45. Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022;603(7902):679-86.

46. Ito K, Piantham C, Nishiura H. Relative Instantaneous Reproduction Number of Omicron SARS-CoV-2 variant with respect to the Delta variant in Denmark. J Med Virol.2022:1-4.

47. Christensen PA, Olsen RJ, Long SW, Snehal R, Davis JJ, Ojeda Saavedra M, et al. Early signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with COVID-19 caused by the Omicron variant of SARS-CoV-2 in Houston, Texas 2022 [2021.12.30.21268560]. Available from: <http://medrxiv.org/content/early/2022/01/04/2021.12.30.21268560.abstract>.

48. Abbott S, Sherratt K, Gerstung M, Funk S. Estimation of the test to test distribution as a proxy for generation interval distribution for the Omicron variant in England 2022 [2022.01.08.22268920]. Available from: <http://medrxiv.org/content/early/2022/01/10/2022.01.08.22268920.abstract>.

49. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 36. 11 February 2022. [Available from: <https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1054357/Technical-Briefing-36-11February2022_v2.pdf>.

50. Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, et al. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa 2022 [updated 2022/06/27. Available from: <https://doi.org/10.1038/s41591-022-01911-2>.

51. Lyngse FP, Kirkeby CT, Denwood M, Christiansen LE, Mølbak K, Møller CH, et al. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households 2022 [2022.01.28.22270044]. Available from: <https://www.medrxiv.org/content/medrxiv/early/2022/01/30/2022.01.28.22270044.full.pdf>.

52. Song JS LJ, Kim M, et al. Serial intervals and household transmission of SARS-CoV-2 Omicron variant, South Korea, 2021. Emerg Infect Dis. 2022 Apr.

53. Lyngse FP, Mortensen LH, Denwood MJ, Christiansen LE, Møller CH, Skov RL, et al. SARS-CoV-2 Omicron VOC Transmission in Danish Households 2021 [2021.12.27.21268278]. Available from: <http://medrxiv.org/content/early/2021/12/27/2021.12.27.21268278.abstract>.

54. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 33 23 Dec 2021 [Available from: <https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1043807/technical-briefing-33.pdf>.

55. Hirose R, Itoh Y, Ikegaya H, Miyazaki H, Watanabe N, Yoshida T, et al. Differences in environmental stability among SARS-CoV-2 variants of concern: Omicron has higher stability 2022 [2022.01.18.476607]. Available from: <http://biorxiv.org/content/early/2022/01/19/2022.01.18.476607.abstract>.

56. Quach C, Blanchard AC, Lamarche J, Audy N, Lamarre V. Should healthcare workers with SARS-CoV-2 household exposures work? A Cohort Study 2022 [2022.01.23.22269719]. Available from: <http://medrxiv.org/content/early/2022/01/24/2022.01.23.22269719.abstract>.

57. Killingley B, Mann A, Kalinova M, Boyers A, Goonawardane N, Zhou J, et al. Safety, tolerability and viral kinetics during SARSCoV-2 human challenge 1 Feb 2022 [Available from: <https://assets.researchsquare.com/files/rs-1121993/v1/2f0e9953-432e-4601-b98e-4ae5c08e025d.pdf?c=1644278080>.

58. Hansen CH, Schelde AB, Moustsen-Helm IR, Emborg H-D, Krause TG, Mølbak K, et al. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study 22 Dec 2021 [Available from: <https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v2.full.pdf>.

59. Gram MA, Emborg H-D, Schelde AB, Friis NU, Nielsen KF, Moustsen-Helms IR, et al. Vaccine effectiveness against SARS-CoV-2 infection and COVID-19-related hospitalization with the Alpha, Delta and Omicron SARS-CoV-2 variants: a nationwide Danish cohort study 2022 [2022.04.20.22274061]. Available from: <http://medrxiv.org/content/early/2022/04/20/2022.04.20.22274061.abstract>.

60. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 34 14 January 2022 [Available from: <https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1046853/technical-briefing-34-14-january-2022.pdf>.

61. Magen O, Waxman JG, Makov-Assif M, Vered R, Dicker D, Hernán MA, et al. Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting 2022 [updated Apr 28PMC9020581]. 2022/04/14:[1603-14]. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMoa2201688>.

62. Regev-Yochay G, Gonen T, Gilboa M, Mandelboim M, Indenbaum V, Amit S, et al. 4th Dose COVID mRNA Vaccines’ Immunogenicity & Efficacy Against Omicron VOC 2022 [2022.02.15.22270948]. Available from: <http://medrxiv.org/content/early/2022/02/15/2022.02.15.22270948.abstract>.

63. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Amir O, Freedman L, et al. Protection by a Fourth Dose of BNT162b2 against Omicron in Israel 2022 [updated May 5PMC9006780]. 2022/04/06:[1712-20]. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMoa2201570>.

64. Gazit S, Saciuk Y, Perez G, Peretz A, Pitzer VE, Patalon T. Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study. BMJ. 2022;377:e071113.

65. Airfinity. Airfinity Science Tracker 2022 [Available from: <https://www.airfinity.com/>.

66. Tartof SY, Slezak JM, Puzniak L, Hong V, Xie F, Ackerson BK, et al. BNT162b2 (Pfizer–Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design 2022 [Available from: <http://dx.doi.org/10.2139/ssrn.4011905>.

67. Thompson MG, Natarajan K, Irving SA, Rowley EA, Griggs EP, Gaglani M, et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 2022 [Available from: <https://doi.org/10.15585/mmwr.mm7104e3>.

68. Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections 2022 [21-34]. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMoa2203965>.

69. Richterman A, Behrman A, Brennan PJ, O’Donnell JA, Snider CK, Chaiyachati KH. Durability of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Booster Vaccine Protection Against Omicron Among Healthcare Workers With a Vaccine Mandate 2022 [cited ciac454. Available from: <https://doi.org/10.1093/cid/ciac454>.

70. Hansen C, Schelde A, Moustsen-Helm I, al. e. Vaccine effectiveness against infection and COVID-19-associated hospitalisation with the Omicron (B.1.1.529) variant after vaccination with the BNT162b2 or mRNA-1273 vaccine: A nationwide Danish cohort study 2022 [30 March 2022:[Available from: <https://doi.org/10.21203/rs.3.rs-1486018/v1>.

71. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern 2021 [Available from: <https://khub.net/documents/135939561/430986542/Effectiveness+of+COVID-19+vaccines+against+Omicron+variant+of+concern.pdf/f423c9f4-91cb-0274-c8c5-70e8fad50074>.

72. Kislaya I, Peralta-Santos A, Borges V, Vieira L, Sousa C, Ferreira B, et al. Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants 22 Feb 2022 [Available from: <https://www.medrxiv.org/content/10.1101/2022.01.31.22270200v1.full.pdf>.

73. Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay JB, et al. Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes 2022 [2021.12.30.21268565]. Available from: <https://www.medrxiv.org/content/medrxiv/early/2022/01/28/2021.12.30.21268565.full.pdf>.

74. UK Health Security Agency. COVID-19 Vaccine Surveillance Report. 27 January 2022. [Available from: <https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1050721/Vaccine-surveillance-report-week-4.pdf>.

75. UK Health Security Agency. Effectiveness of 3 doses of COVID-19 vaccines against symptomatic COVID-19 and hospitalisation in adults aged 65 years and older 2022 [Available from: <https://khub.net/documents/135939561/338928724/Effectiveness+of+3+doses+of+COVID-19+vaccines+against+symptomatic+COVID-19+and+hospitalisation+in+adults+aged+65+years+and+older.pdf/ab8f3558-1e16-465c-4b92-56334b6a832a>.

76. McMenamin ME, Nealon J, Lin Y, Wong JY, Cheung JK, Lau EHY, et al. Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong 2022 [2022.03.22.22272769]. Available from: <http://medrxiv.org/content/early/2022/03/24/2022.03.22.22272769.abstract>.

77. Gazit S, Saciuk Y, Perez G, Peretz A, Pitzer VE, Patalon T. Relative Effectiveness of Four Doses Compared to Three Dose of the BNT162b2 Vaccine in Israel 2022 [2022.03.24.22272835]. Available from: <http://medrxiv.org/content/early/2022/03/24/2022.03.24.22272835.abstract>.

78. CDC. Updates on COVID-19 Vaccine Effectiveness during Omicron 2022 [Available from: <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-09-01/04-COVID-Link-Gelles-508.pdf>.

79. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, AlMukdad S, Tang PJ, Hasan MR, et al. Effectiveness of BNT162b2 and mRNA-1273 COVID-19 boosters against SARS-CoV-2 Omicron (B.1.1.529) infection in Qatar 2022 [2022.01.18.22269452]. Available from: <http://medrxiv.org/content/early/2022/01/24/2022.01.18.22269452.abstract>.

80. Nordström P, Ballin M, Nordström A. Effectiveness of a fourth dose of mRNA COVID-19 vaccine against all-cause mortality in long-term care facility residents and in the oldest old: A nationwide, retrospective cohort study in Sweden: Elsevier; [Available from: <https://doi.org/10.1016/j.lanepe.2022.100466>.

81. World Health Organisation (WHO). Weekly epidemiological update on COVID-19 - 17 August 2022. Edition 105 2022 [Available from: <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---17-august-2022>.

82. Reynolds CJ, Pade C, Gibbons JM, Otter AD, Lin K-M, Sandoval DM, et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure [Available from: <https://www.science.org/doi/abs/10.1126/science.abq1841>.

83. Geurts van Kessel C, Geers D, Schmitz K, Mykytyn A, Lamers M, Bogers S, et al. Divergent SARS CoV-2 Omicron-specific T- and B-cell responses in COVID-19 vaccine recipients: medRxiv; 2021 [updated 2021. Available from: <https://doi.org/10.1101/2021.12.27.21268416>.

84. Nemet I, Kliker L, Lustig Y, Zuckerman N, Erster O, Cohen C, et al. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection 2021 [updated Dec 29. 2021/12/30:[Available from: <https://www.nejm.org/doi/pdf/10.1056/NEJMc2119358?articleTools=true>.

85. Perez-Then E, Lucas C, Monteiro VS, Miric M, Brache V, Cochon L, et al. Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: the Dominican Republic Experience: medRxiv; 2021 [updated 2021. Available from: <https://www.medrxiv.org/content/medrxiv/early/2021/12/29/2021.12.27.21268459.full.pdf>.

86. Tada T, Zhou H, Dcosta B, Samanovic M, Chivukula V, Herati R, et al. Increased resistance of SARS-CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited and Therapeutic Antibodies: bioRxiv; 2021 [updated 2021. Available from: <https://doi.org/10.1101/2021.12.28.474369>.

87. Zeng C, Evans J, Chakravarthy K, Qu P, Reisinger S, Song Nj, et al. mRNA Booster Vaccines Elicit Strong Protection Against SARS-CoV-2 Omicron Variant in Cancer Patients: medRxiv; 2021 [updated 2021. Available from: <https://doi.org/10.1101/2021.12.28.21268398>.

88. Zhang L, Li Q, Liang Z, Li T, Liu S, Cui Q, et al. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron: Taylor & Francis; 2022 [updated 2022/12/31. 1-5]. Available from: <https://doi.org/10.1080/22221751.2021.2017757>.

89. UK Health Security Agency. Risk assessment for SARS-CoV-2 variant: VUI-22JAN-01 (BA.2). 26 January 2022. [Available from: <https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1051013/26-january-2022-risk-assessment-for-VUI-22JAN-01_BA.2.pdf>.

90. Yu J, Collier A-rY, Rowe M, Mardas F, Ventura JD, Wan H, et al. Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants 2022 [2022.02.06.22270533]. Available from: <http://medrxiv.org/content/early/2022/02/07/2022.02.06.22270533.abstract>.

91. Mykytyn AZ, Rissmann M, Kok A, Rosu ME, Schipper D, Breugem TI, et al. Omicron BA.1 and BA.2 are antigenically distinct SARS-CoV-2 variants 2022 [2022.02.23.481644]. Available from: <http://biorxiv.org/content/early/2022/02/24/2022.02.23.481644.abstract>.

92. Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection 2022 [2022.04.30.489997]. Available from: <https://www.biorxiv.org/content/biorxiv/early/2022/06/14/2022.04.30.489997.full.pdf>.

93. Canetti M, Barda, N., Gilboa, M., et al. . Immune Response and Clinical Outcomes of BNT162b2 and mRNA1273 Fourth Dose COVID-19 Vaccines; Three Months Follow-up, 11 August 2022, PREPRINT (Version 1) 2022 [Available from: <https://doi.org/10.21203/rs.3.rs-1946528/v1>.

94. Xie X, Zou J, Liu M, Ren P, Shi P-Y. Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of mRNA vaccine 2022 [2022.07.29.502055]. Available from: <https://www.biorxiv.org/content/biorxiv/early/2022/07/29/2022.07.29.502055.full.pdf>.

95. Cheng HL, Lim SM, Jia H, Chen MW, Ng SY, Gao X, et al. Rapid Evaluation of Vaccine Booster Effectiveness against SARS-CoV-2 Variants [e02257-22]. Available from: <https://journals.asm.org/doi/abs/10.1128/spectrum.02257-22>.

96. Qu P, Faraone JN, Evans JP, Zheng Y-M, Yu L, Ma Q, et al. Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants 2022 [Available from: <https://www.nejm.org/doi/full/10.1056/NEJMc2210546>.

97. Bajaj R, Yang Z, Hammer V, Pöschel S, Bieber K, Salker MS, et al. Immune dynamics at single cell protein level after delta/omicron infection in COVID-19 vaccinated convalescent individuals 2022 [2022.09.05.506626]. Available from: <https://www.biorxiv.org/content/biorxiv/early/2022/09/06/2022.09.05.506626.full.pdf>.

98. Young B, Fong S-W, Chang ZW, Tan KS, Rouers A, Goh YS, et al. Comparison of the clinical features, viral shedding and immune response in vaccine breakthrough infection by the Omicron and Delta variants 2022 [Available from: <https://doi.org/10.21203/rs.3.rs-1281925/v1>.

99. Altarawneh H, Chemaitelly H, Tang P, Hasan MR, Qassim S, Ayoub HH, et al. Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant 2022 [2022.01.05.22268782]. Available from: <http://medrxiv.org/content/early/2022/01/06/2022.01.05.22268782.abstract>.

100. Imperial College COVID-19 response team. Report 49 - Growth, population distribution and immune escape of Omicron in England. 16 December 2021. [Available from: <https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-49-Omicron/>.

101. Katherine E. Fleming-Dutra M. COVID-19 epidemiology in children ages 6 months–4 years: National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention; 2022 [updated 17 June 2022. Available from: <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-06-17-18/02-covid-fleming-dutra-508.pdf>.

102. Payne AB, Gilani Z, Godfred-Cato S, Belay ED, Feldstein LR, Patel MM, et al. Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2 2021 [e2116420-e]. Available from: <https://doi.org/10.1001/jamanetworkopen.2021.16420>.

103. Morris CP, Eldesouki RE, Fall A, Gaston DC, Norton JM, Gallagher ND, et al. SARS-CoV-2 reinfections during the Delta and Omicron waves: The American Society for Clinical Investigation; 2022 [updated 09/01/. Available from: <https://doi.org/10.1172/jci.insight.162007>.

104. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. Coronavirus Pandemic (COVID-19) 2021 [Available from: <https://ourworldindata.org/coronavirus>.

105. Wu Y, Kang L, Guo Z, Liu J, Liu M, Liang W. Incubation Period of COVID-19 Caused by Unique SARS-CoV-2 Strains: A Systematic Review and Meta-analysis. JAMA Network Open. 2022;5(8):e2228008-e.

106. Buchholz U, an der Heiden M. Serial interval in households infected with SARS-CoV-2 variant B.1.1.529 (Omicron) are even shorter compared to Delta: Cambridge University Press; 2022 [2022/08/05:[1-5]. Available from: <https://www.cambridge.org/core/article/serial-interval-in-households-infected-with-sarscov2-variant-b11529-omicron-are-even-shorter-compared-to-delta/60AA52E3C01DEFA8AABC7B51B186A639>.

107. Gunnhild Helmsdal, Olga K Hansen, Lars F Møller, Debes H Christiansen, Maria Skaalum Petersen, Marnar F Kristiansen. Omicron outbreak at a private gathering in the Faroe Islands infecting 21 of 33 triple-vaccinated healthcare workers 23 Dec 2021 [Available from: <https://www.medrxiv.org/content/medrxiv/early/2021/12/23/2021.12.22.21268021.full.pdf>.

108. Brandal LT, MacDonald E, Veneti L, Ravlo T, Lange H, Naseer U, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021 Sweden2021 [Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=prem&NEWS=N&AN=34915975>.

109. Jansen L, Tegomoh B, Lange K, Showalter K, Figliomeni J, Abdalhamid B, et al. Investigation of a SARS-CoV-2 B.1.1.529 (Omicron) Variant Cluster - Nebraska, November-December 2021. MMWR Morb Mortal Wkly Rep. 2021;70(5152):1782-4.

110. Backer JA, Eggink D, Andeweg SP, Veldhuijzen IK, van Maarseveen N, Vermaas K, et al. Shorter serial intervals in SARS-CoV-2 cases with Omicron BA.1 variant compared with Delta variant, the Netherlands, 13 to 26 December 2021. Euro Surveill. 2022;27(6).

111. Del Águila-Mejía J, Wallmann R, Calvo-Montes J, Rodríguez-Lozano J, Valle-Madrazo T, Aginagalde-Llorente A. Secondary Attack Rate, Transmission and Incubation Periods, and Serial Interval of SARS-CoV-2 Omicron Variant, Spain. Emerg Infect Dis. 2022;28(6):1224-8.

112. Kremer C, Braeye T, Proesmans K, André E, Torneri A, Hens N. Observed serial intervals of SARS-CoV-2 for the Omicron and Delta variants in Belgium based on contact tracing data, 19 November to 31 December 2021 2022 [2022.01.28.22269756]. Available from: <http://medrxiv.org/content/early/2022/01/30/2022.01.28.22269756.abstract>.

113. National Institute of Infectious Diseases J. Active epidemiological investigation on SARS-CoV-2 infection caused by Omicron variant (Pango lineage B.1.1.529) in Japan: preliminary report on infectious period. 5 January 2022. [Available from: [www.niid.go.jp/niid/en/2019-ncov-e/10884-covid19-66-en.html](https://mohgovtnz.sharepoint.com/sites/HealthEMIS/covid19/STALibrary3/Request%20for%20Advice%20(from%20251)/0563%20VoC%2049%20Variant%20of%20Concern%20Update%20(13%20Sep%202022)/www.niid.go.jp/niid/en/2019-ncov-e/10884-covid19-66-en.html).

114. Puhach O, Adea K, Hulo N, Sattonnet P, Genecand C, Iten A, et al. Infectious viral load in unvaccinated and vaccinated patients infected with SARS-CoV-2 WT, Delta and Omicron 2022 [2022.01.10.22269010]. Available from: <http://medrxiv.org/content/early/2022/01/11/2022.01.10.22269010.abstract>.

115. Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. The Lancet. 2022;399(10335):1618-24.

116. Akavian I, Nitzan I, Talmy T, Nitecki M, Gendler S, Besor O. SARS-CoV-2 Omicron Variant: Clinical Presentation and Occupational Implications in Young and Healthy IDF Soldiers. Military Medicine. 2022:usac263.

117. Elliott P, Eales O, Bodinier B, Tang D, Wang H, Jonnerby J, et al. Post-peak dynamics of a national Omicron SARS-CoV-2 epidemic during January 2022 2022 [2022.02.03.22270365]. Available from: <http://medrxiv.org/content/early/2022/02/06/2022.02.03.22270365.abstract>.

118. Elliott P. EO, Bodinier B., et al. Post-peak dynamics of a national Omicron SARS-CoV-2 epidemic during January 2022. REACT-1 study. Round 17. 2022. [Available from: <https://www.imperial.ac.uk/media/imperial-college/institute-of-global-health-innovation/R17_final.pdf>.

119. Kim M-K, Lee B, Choi YY, Um J, Lee K-S, Sung HK, et al. Clinical Characteristics of 40 Patients Infected With the SARS-CoV-2 Omicron Variant in Korea: The Korean Academy of Medical Sciences; 2022 [updated 1/. 0]. Available from: <https://doi.org/10.3346/jkms.2022.37.e31>.

120. Kuhlmann C, Mayer CK, Claassen M, Maponga TG, Sutherland AD, Suliman T, et al. Breakthrough Infections with SARS-CoV-2 Omicron Variant Despite Booster Dose of mRNA Vaccine 2021 [Available from: <https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3981711>.

121. SARS-CoV-2 B.1.1.529 (Omicron) Variant — United States, December 1–8, 2021 2021 [Available from: <https://www.cdc.gov/mmwr/volumes/70/wr/mm7050e1.htm>.

122. Li A, Maier A, Carter M, Hugh Guan T. Omicron and S-Gene Target Failure Cases in the Highest COVID-19 Case Rate Region in Canada - December 2021 2021 [updated Dec 29. 2021/12/30:[Available from: <https://onlinelibrary.wiley.com/doi/10.1002/jmv.27562>.

123. Iacobucci G. Covid-19: Runny nose, headache, and fatigue are commonest symptoms of omicron, early data show England2021 [n3103]. Available from: <https://www.bmj.com/content/375/bmj.n3103#:~:text=Data%20released%20on%2016%20December,%2C%20sneezing%2C%20and%20sore%20throat>.

124. Akaishi T, Kushimoto S, Katori Y, Sugawara N, Egusa H, Igarashi K, et al. COVID-19-Related Symptoms during the SARS-CoV-2 Omicron (B.1.1.529) Variant Surge in Japan. The Tohoku Journal of Experimental Medicine. 2022;258(2):103-10.

125. Hajjo R, AbuAlSamen MM, Alzoubi HM, Alqutob R. The Epidemiology of Hundreds of Individuals Infected with Omicron BA.1 in Middle-Eastern Jordan 2022 [2022.01.23.22269442]. Available from: <http://medrxiv.org/content/early/2022/01/25/2022.01.23.22269442.abstract>.

126. Vihta K-D, Pouwels KB, Peto TE, Pritchard E, House T, Studley R, et al. Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom 2022 [2022.01.18.22269082]. Available from: <https://www.medrxiv.org/content/medrxiv/early/2022/02/04/2022.01.18.22269082.full.pdf>.

127. Cloete J, Kruger A, Masha M, Plessis NMd, Mawela D, Tshukudu M, et al. Rapid rise in paediatric COVID-19 hospitalisations during the early stages of the Omicron wave, Tshwane District, South Africa 21 Dec 2021 [Available from: <https://www.medrxiv.org/content/10.1101/2021.12.21.21268108v1.full.pdf>.

128. Office for National Statistics UK. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1 June 2022 2022 [Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1june2022>.

129. World Health Organisation (WHO). Severity of disease associated with Omicron variant as compared with Delta variant in hospitalized patients with suspected or confirmed SARS-CoV-2 infection 2022 [updated 7 June 2022. Available from: <https://www.who.int/publications/i/item/9789240051829>.

130. Skarbinski J, Wood MS, Chervo TC, Schapiro JM, Elkin EP, Valice E, et al. Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: A retrospective cohort study. The Lancet Regional Health – Americas. 2022;12.

131. Agency for Clinical Innovation. COVID-19 Critical Intelligence Unit: Living Evidence - SARS-CoV-2 variants: NSW Agency for Clinical Innovation; 2022 [updated 2 September 2022. Available from: <https://aci.health.nsw.gov.au/covid-19/critical-intelligence-unit/sars-cov-2-variants>.

132. Lewnard JA, Hong V, Tartof SY. Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome. medRxiv. 2022:2022.07.31.22278258.

133. Davies M-A, Morden E, Rosseau P, Arendse J, Bam J-L, Boloko L, et al. Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa 2022 [2022.06.28.22276983]. Available from: <https://www.medrxiv.org/content/medrxiv/early/2022/06/28/2022.06.28.22276983.full.pdf>.

134. GOV.UK. Healthcare in United Kingdom 2022 [updated 11 August 2022. Available from: <https://coronavirus.data.gov.uk/details/healthcare>.

135. Centers for Disease Control and Prevention (CDC). COVID DATA TRACKER WEEKLY REVIEW COVID-192022 [updated 22 July 2022. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/past-reports/07222022.html>.

136. Mahase E. Covid-19: What we know about the BA.4 and BA.5 omicron variants 2022 [o1969]. Available from: <http://www.bmj.com/content/378/bmj.o1969.abstract>.

137. Kahn F, Bonander C, Moghaddassi M, Rasmussen M, Malmqvist U, Inghammar M, et al. Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities – surveillance results from southern Sweden 2022 [2022.02.03.22270389]. Available from: <http://medrxiv.org/content/early/2022/02/04/2022.02.03.22270389.abstract>.

138. Fall A, Eldesouki RE, Sachithanandham J, Paul Morris C, Norton JM, Gaston DC, et al. A Quick Displacement of the SARS-CoV-2 variant Delta with Omicron: Unprecedented Spike in COVID-19 Cases Associated with Fewer Admissions and Comparable Upper Respiratory Viral Loads 2022 [2022.01.26.22269927]. Available from: <http://medrxiv.org/content/early/2022/01/28/2022.01.26.22269927.abstract>.

139. Veneti L, Bøås H, Bråthen Kristoffersen A, Stålcrantz J, Bragstad K, Hungnes O, et al. Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022 2022 [2200077]. Available from: <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2022.27.4.2200077>.

140. Vieillard-Baron A, Flicoteaux R, Salmona M, Annane D, Ayed S, Azoulay E, et al. Epidemiological characteristics and severity of omicron variant cases in the APHP critical care units 2022 [2022.01.25.22269839]. Available from: <http://medrxiv.org/content/early/2022/01/28/2022.01.25.22269839.abstract>.

141. Sheikh A, Kerr S, Woolhouse M, McMenamin J, Robertson C. Severity of Omicron variant of concern and vaccine effectiveness against symptomatic disease: national cohort with nested test negative design study in Scotland 23 Dec 2021 [Available from: <https://www.pure.ed.ac.uk/ws/portalfiles/portal/245818096/Severity_of_Omicron_variant_of_concern_and_vaccine_effectiveness_against_symptomatic_disease.pdf>.

142. Public Health Ontario. Early Estimates of Omicron Severity in Ontario based on a Matched Cohort Study, November 22 to December 17, 2021 [Available from: <https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-epi-enhanced-estimates-omicron-severity-study.pdf?sc_lang=en>.

143. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing: Update on hospitalisation and vaccine effectiveness for Omicron VOC-21NOV-01 (B.1.1.529) <https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1044481/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf31> December 2021 [Available from: <https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1045619/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf>.

144. Young-Xu Y. Effectiveness of mRNA COVID-19 Vaccines against Omicron among Veterans 2022 [2022.01.15.22269360]. Available from: <http://medrxiv.org/content/early/2022/01/18/2022.01.15.22269360.abstract>.

145. Peralta Santos A, Pinto Leite P, Casaca P, Fernandes E, Freire Rodrigues E, Moreno J, et al. Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta (B.1.617.2) 2022 [2022.01.20.22269406]. Available from: <http://medrxiv.org/content/early/2022/01/25/2022.01.20.22269406.abstract>.

146. Krutikov M, Stirrup O, Nacer-Laidi H, Azmi B, Fuller C, Tut G, et al. Outcomes of SARS-CoV-2 Omicron infection in residents of Long-Term Care 2022 [2022.01.21.22269605]. Available from: <http://medrxiv.org/content/early/2022/01/23/2022.01.21.22269605.abstract>.

147. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 35. 28 January 2022. [Available from: <https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1050999/Technical-Briefing-35-28January2022.pdf>.

148. Davies M-A, Kassanjee R, Rosseau P, Morden E, Johnson L, Solomon W, et al. Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa 2022 [2022.01.12.22269148]. Available from: <http://medrxiv.org/content/early/2022/01/12/2022.01.12.22269148.abstract>.

149. Català M, Coma E, Alonso S, Andrés C, Blanco I, Antón A, et al. Transmissibility, hospitalization, and intensive care admissions due to omicron compared to delta variants of SARS-CoV-2 in Catalonia: A cohort study and ecological analysis. Front Public Health. 2022;10:961030.

150. Iuliano AD BJ, Boehmer TK, et al. . Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods — United States, December 2020–January 2022. [Available from: <http://dx.doi.org/10.15585/mmwr.mm7104e4>.

151. Bager P, Wohlfahrt J, Bhatt S, Edslev SM, Sieber RN, Ingham AC, et al. Reduced Risk of Hospitalisation Associated With Infection With SARS-CoV-2 Omicron Relative to Delta: A Danish Cohort Study 2022 [Available from: <https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4008930>.

152. Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California 11 Jan 2022 [Available from: <https://www.medrxiv.org/content/10.1101/2022.01.11.22269045v1.full.pdf>.

153. Ferguson N, Ghani A, Hinsley W, Volz E. Report 50: Hospitalisation risk for Omicron cases in England [Available from: <https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2021-12-22-COVID19-Report-50.pdf>.

154. Torjesen I. Covid-19: Omicron variant is linked to steep rise in hospital admissions of very young children 2022 [o110]. Available from: <https://www.bmj.com/content/bmj/376/bmj.o110.full.pdf>.

155. UK Scientific Advisory Group for Emergencies. CO-CIN: Child admissions and severity by epoch CO-CIN update 6 January 2022 [Available from: <https://www.gov.uk/government/publications/co-cin-child-admissions-and-severity-by-epoch-co-cin-update-january-2022-6-january-2022>.

156. Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND, Xu R. COVID infection severity in children under 5 years old before and after Omicron emergence in the US 2022 [2022.01.12.22269179]. Available from: <http://medrxiv.org/content/early/2022/01/13/2022.01.12.22269179.abstract>.

157. Martin B, DeWitt PE, Russell S, Sanchez-Pinto LN, Haendel MA, Moffitt R, et al. Acute upper airway disease in children with the omicron (B.1.1.529) variant of SARS-CoV-2: a report from the National COVID Cohort Collaborative (N3C) 2022 [Available from: <https://www.medrxiv.org/content/medrxiv/early/2022/01/30/2022.01.27.22269865.full.pdf>.

158. Böncüoğlu E, Kiymet E, Şahinkaya Ş, Cem E, Yilmaz Çelebi M, Gülderen M, et al. Did Hospitalization Age Decrease in Children in the Omicron (B.1.1.529) Era? 2022 [Available from: <https://journals.lww.com/pidj/Fulltext/2022/09000/Did_Hospitalization_Age_Decrease_in_Children_in.32.aspx>.

159. Public Health Scotland. COVID-19 Statistical Report As at 5 January 2022. 7 January 2022 [Available from: <https://www.publichealthscotland.scot/publications/covid-19-statistical-report/covid-19-statistical-report-7-january-2022/>.

160. Jassat W KS, Mudara C, et al., . Clinical Severity of COVID-19 Patients Admitted to Hospitals in Gauteng, South Africa During the Omicron-Dominant Fourth Wave. 29 Dec 2021 [Available from: <https://ssrn.com/abstract=3996320>.

161. Goga A, Bekker L-G, Garrett N, Reddy T, Yende-Zuma N, Fairall L, et al. Breakthrough Covid-19 infections during periods of circulating Beta, Delta and Omicron variants of concern, among health care workers in the Sisonke Ad26.COV2.S vaccine trial, South Africa 2021 [2021.12.21.21268171]. Available from: <http://medrxiv.org/content/early/2021/12/22/2021.12.21.21268171.abstract>.

162. Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study: Elsevier; [437-46]. Available from: <https://doi.org/10.1016/S0140-6736(22)00017-4>.

163. Aleem A, Akbar Samad AB, Slenker AK. Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19) Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC.; 2022 [Available from: <https://pubmed.ncbi.nlm.nih.gov/34033342/>.

164. Chen J, Wang R, Gilby NB, Wei G-W. Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance United States2021 [Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm&NEWS=N&AN=34873578>.

165. Ferreira I, Kemp SA, Datir R, Saito A, Meng B, Rakshit P, et al. SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion 2021 [updated Sep 17PMC8420622]. 989-94]. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420622/>.

166. Kimura I, Kosugi Y, Wu J, Zahradnik J, Yamasoba D, Butlertanaka EP, et al. The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance 2022 [updated Jan 11; cited Declaration of interests The authors declare no competing interests. PMC8683271]. 20211218:[110218]. Available from: <https://www.sciencedirect.com/science/article/pii/S2211124721017228?via%3Dihub>.

167. Wang Q, Guo Y, Iketani S, Nair MS, Li Z, Mohri H, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5 2022 [2022.05.26.493517]. Available from: <https://www.biorxiv.org/content/biorxiv/early/2022/06/27/2022.05.26.493517.full.pdf>.

168. Moghadasi SA, Heilmann E, Moraes SN, Kearns FL, von Laer D, Amaro RE, et al. Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors 2022 [2022.08.07.503099]. Available from: <https://www.biorxiv.org/content/biorxiv/early/2022/08/08/2022.08.07.503099.full.pdf>.

169. Wang L, Berger NA, Davis PB, Kaelber DC, Volkow ND, Xu R. COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022 2022 [2022.06.21.22276724]. Available from: <https://www.medrxiv.org/content/medrxiv/early/2022/06/22/2022.06.21.22276724.full.pdf>.

170. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England - Technical briefing 40 2022 [updated 8 April 2022. Available from: <https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1067672/Technical-Briefing-40-8April2022.pdf>.

171. Leuzinger K, Roloff T, Egli A, Hirsch HH. Impact of SARS-CoV-2 Omicron on Rapid Antigen Testing Developed for Early-Pandemic SARS-CoV-2 Variants [e02006-22]. Available from: <https://journals.asm.org/doi/abs/10.1128/spectrum.02006-22>.

172. Wells CR, Pandey A, Moghadas SM, Singer BH, Krieger G, Heron RJL, et al. Comparative analyses of eighteen rapid antigen tests and RT-PCR for COVID-19 quarantine and surveillance-based isolation 2022 [updated 2022/07/09. 84]. Available from: <https://doi.org/10.1038/s43856-022-00147-y>.

1. Includes BA.1, BA.2, BA.3, BA.4, BA.5 and descendent lineages. [↑](#footnote-ref-2)
2. 95% Credible Interval [↑](#footnote-ref-3)
3. 95% Credible Interval [↑](#footnote-ref-4)
4. adjusted for age, sex, socioeconomic status, vaccination status and clinical risk factors. [↑](#footnote-ref-5)
5. adjusted for vaccination status and region [↑](#footnote-ref-6)
6. Controlled for factors known to be associated with severity (age, presence of comorbidity, sex, province and healthcare sector) and adjusted for the number of days between the date of specimen collection and date of hospital admission, known prior SARS-CoV-2 infection and SARS-CoV-2 vaccination status. [↑](#footnote-ref-7)
7. Controlled for factors known to be associated with disease severity (age, presence of co-morbidity, sex, province and healthcare sector), and adjusted for number of days between date of specimen collection and date of hospital admission, known prior SARS-CoV-2 infection and SARS-CoV-2 vaccination status. [↑](#footnote-ref-8)